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The ubiquitous environmental pollutant Dibutyl Phthalate (DBP) is a known to have anti-androgenic like 
properties. DBP exposure has been linked to a range of developmental disorders in males such as 
hypospadias (defect of the penis) and cryptorchidism (undescended testes). Humans are exposed to DBP 
daily; therefore, it is essential to fully understand the role DBP in the pathogenesis of these 
developmental disorders. The mechanism of toxicity has yet to be fully established; however, DBP has 
been shown to reduce testosterone biosynthesis and is thought to disrupt the embryological 
androgen:estrogen ratio. The present study developed and characterized a LC-540 Leydig cell line model 
system. This model system was used to investigate the effects of DBP at physiologically relevant 
concentrations on key genes of testosterone biosynthesis via the use of Nanostring® nCounter 
technology. The metabolism of DBP was investigated using HPLC to identify if any potentially estrogenic 
metabolites are produced. The estrogenicity of DBP was investigated using a MCF-7 proliferation assay. 
The LC-540 model system is able to produce detectable quantities of testosterone with and without 
external stimulation in culture. The metabolism of DBP did not produce any potentially estrogenic 
metabolites; however, the LC-540 Phase I and Phase II processes were identified. DBP appears to be 
slightly estrogenic and promotes growth of MCF-7 cells. Key genes in testosterone biosynthesis are 
changed following exposure to DBP. The gene that codes for testosterone biosynthesis (hsd17b3) is 
down-regulated at normal daily exposure concentrations and occupational exposure concentrations. 
The gene that codes for 17β-estradiol synthesis (cyp19a1) is up-regulated at occupational exposure 
concentrations. The likely result of these gene changes is the feminization of males which explains the 
role of DBP in the pathogenesis of hypospadias and cryptorchidism. The present study is the first 
evidence of dual gene regulatory changes following DBP exposure at physiologically relevant exposure 
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1.1 A Brief History of Dibutyl Phthalate (DBP) 
The phthalate esters, including DBP (Fig. 1.1), were first used in the 1930s1,2 as plasticizers to replace the 
widely used camphor which had a tendency to produce an unpleasant odour.3 Phthalate esters were 
consumer friendly plasticizers as they were seen at the time to be colourless, odourless, non-volatile 
and potentially non-toxic. These properties likely contributed to the mass production and proliferation 
of plastic products seen from the 1930s onwards. The toxicity of DBP was first demonstrated in 1970 
when chick embryos exposed to high levels of DBP produced a significant increase in teratogenicity 
(birth defects).4 A key study in rats linked embryological exposure of DBP and testicular atrophy in male 
pups born to pregnant dams exposed to DBP orally.5 Research into the toxicity of DBP continued into 
the 1990s6,7 ensuring legislative bodies in key jurisdictions (e.g. USA) undertook their own 
investigations. The USA1 and the European Union (EU)8 both legislated against use of phthalates in 
children’s toys in 2009 and 1999 respectively.9  
In the 21st century the general population has become increasingly aware of the potential toxic risks of 
plasticizers, particularly bisphenol A (BPA) and the phthalates esters.10 The ensuing condemnation and 
consumer pressure has led to the plastics industries moving toward products containing additives with 
significantly less toxicity (e.g. dioctyl terephthalate, DOTP).11 
1.2 DBP Production, Function and Use 
DBP is synthesized commercially by reacting phthalic acid with excess butan-1-ol and sulphuric acid as a 
catalyst (Fig. 1.1). The worldwide production of DBP in 2007 was approximately 9 million tons.1 DBP is 
produced primarily in China and the United States; however, both governments are  
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Figure 1.1: The commercial synthesis of DBP. The sulphuric acid catalyst protonates the carboxylic acid. The 
butanol is deprotonated and attacks the carbonyl and the water acts as the leaving group in the Sn2 reaction. 
reluctant to publish data on production volumes. The volume productions at the present time are 
unknown. EU trends suggest a significant decrease in production over the last 15 years (Fig. 1.2), with 
over 50,000 tonnes in 1994 compared to less than 10,000 tonnes in 2007.12 The decline in DBP 
production can almost certainly be attributed to consumer pressure relating to potentially toxic plastic 
additives and the subsequent replacement of DBP with less toxic phthalate alternatives (e.g. DOTP).11  







Figure 1.2: The production of DBP in the European Union from 1994-2007. The production has been steadily 

































1.2.1 Uses of DBP 
DBP is used primarily as a plasticizer to increase the pliability and strength of commercial plastic 
products; most commonly in polyvinyl chloride (PVC) and nitrocellulose polymers. PVC is the world’s 
second most produced and used commercial polymer with an annual global production of 31 million 
tonnes,13 with 40% of its market dedicated to pipes and fittings.14 Commercial PVC production has three 
key steps: synthesis of vinyl chloride monomers, polymerization of the monomer units and the addition 
of plasticizers (most commonly phthalates).15 Pure PVC polymer is a non-thermally stable compound 
that is highly brittle and prone to fractures and decomposition.15 The decomposition of pure PVC occurs 
when the branching chains of the polymers react internally to release HCl. This significantly reduces the 
polymer strength and leads to rapid degradation of the polymer.16 Therefore, treatment with phthalates 
is essential before PVC can be used in most commercial applications. PVC is plasticized by heating the 
pure PVC resin in the plasticizer solution until the PVC has dissolved. This ensures thorough 
incorporation of the plasticizer into the polymer matrix.16 
The mechanism of action of DBP as a plasticizer has been a key area of polymer research. There are 
several  theories; most prominent of which is the lubrication theory.16 This theory states: during the 
heating and co-polymerization processes, the plasticizers (i.e. phthalates) diffuse into the polymer 
matrix, preventing branch chain interactions; thereby, acting as a shield to prevent the loss of HCl. This 
results in a significant reduction in polymer degradation. The addition of phthalates lowers the glass 
transition (Tg); the temperature at which a rigid, solid polymer enters a rubber-like semisolid state which 
is flexible, extendible and soft. The DBP-treated PVC is then able to be used in a variety of products, 
ranging from children’s toys, water piping, plastic packaging, medical products and equipment, and 
carpeting. 
The cosmetics and personal care products industry also use DBP extensively.17 DBP has a duel role in 
many cosmetic products; e.g. DBP in nail varnish acts as both a solvent for the dyes and as a plasticizer 
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for the polish itself, ensuring that the applied product is not brittle. Body sprays have also been known 
to use DBP as a solvent, but the prevalence of its use is unknown as many of the formulations are 
proprietary blends that do not require disclosure of their composition on the product label. 
DBP has also been used in a military setting; e.g. conflicts in Asia during World War Two up until the 
Vietnam War,18,19 especially during the Malayan Emergency of 1948-1960.20 The primary use of DBP 
during these conflicts was as an acaricide and sealant for the seams of military uniforms of troops 
involved in jungle operations to prevent infections from trombiculid mites (e.g. Leptotrombidium 
delicense) which are the vectors for bush typhus (Orientia tsutsugamushi). This rickettsial infection 
causes severe muscle soreness, gastrointestinal pain and diarrhoea which are potentially fatal. The use 
of DBP was essential at the time to maintain jungle operations as any troops infected with bush typhus 
were unable to undertake military operations. 
1.3 DBP Toxicology 
DBP has been classified as an endocrine disrupting chemical (EDC); particularly affecting the synthesis 
and regulation of the androgenic (male sex) hormones essential for male growth and development.1 The 
mechanism of toxicity has yet to be fully established but there is a body of evidence that suggest DBP 
has a major disruptive effect on the embryological synthesis of testosterone during male sexual 
development.1 
DBP has very low toxicity: LD50 [rat oral] = 20,000 mg/kg body weight (bw). This does not pose a 
significant risk of death. Indeed, the likely human LD50 based on rat data suggests the lethal toxic dose 
would be in far excess of a feasible human daily exposure concentration; i.e. rat LD50 = 20,000 mg/kg 
bw, based on a 70 kg human bw this means a dose of 1.4 x 106 mg (1.4 kg) would be needed to kill a 
human. However, DBP is more toxic to embryos, with the incidence of still births’ increasing significantly 
following DBP exposure to pregnant rats at doses ranging from 630-3000 mg/kg bw.6,21 
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There are few toxicological data available for humans but there has been a significant body of work in 
animals. The data are highly variable among individual experiments and experimental conditions. The 
observable effects and the sensitivity vary between embryological and postnatal exposure. 
The postnatal exposure studies demonstrate that the toxic effects of DBP primarily affect the sexual 
development of males (e.g. reductions in testes weight, testicular atrophy).22  The no observable 
adverse effect level (NOAEL, the highest dose at which there are no observable toxic effects), ranges 
from 500-2000 mg/kg bw/day.22,23 Whereas, the lowest observable adverse effect level (LOEAL, the 
lowest dose at which significant toxic effects are observed), ranges from 2000-2400 mg/kg bw/day 
(table 2.1).23,24 
There does not appear to be a clear dose response relationship in postnatal exposures to DBP in rats 
with serious morphological effects observable at a range of doses (e.g. from 500-2000 mg/kg bw/day), 
whereas some studies report no adverse effects at doses of 2000 mg/kg bw/day. 23,24  
Embryological DBP exposure (Table 2.2), however, shows a far more sensitive response at lower doses 
of DBP, with significant adverse effects observable at levels well below the postnatal NOEAL.21  
Decreases in testes weight were observed at doses as low as 100 mg/kg bw/day and feminizing effects 
(e.g reductions in anogenital distance, AGD), were observable between 500-750 mg/kg bw/day.25 A dose 
response relationship occurs between gestational day exposure and increasing toxicity of DBP. Serious 
developmental toxicity (e.g. permanent morphological changes) was readily observed when exposure to 
DBP occurred later in gestation; e.g. from gestation day (Gd) 12 onward. Exposure from Gd 0-8 
produced developmental toxicity at 500 mg/kg bw/day with severe effects at 750 mg/kg bw/day.26 
Conversely, exposure from Gd 12-21 produced toxic effects at 100 mg/kg bw/day with the more severe 
morphological effects observed as low as 250 mg/kg bw/day (the same dose at which no toxic effects 
were observed from Gd 0-8).27 The early stages of male gestation do not require the androgenic 
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hormones (e.g. testosterone), whereas at Gd 12-21, testosterone is responsible for myriad 
developmental processes. Therefore, if DBP toxicity occurs through a mechanism of diminishing 
testosterone production, it is unsurprising that DBP’s toxic effects are far more potent during the key 
sexual development period. 
Due to the developmental toxicity of DBP and the greatest NOEAL of 50 mg/kg bw/day, the minimal risk 
level (MRL) has been set at 0.5 mg/kg bw/day.1 The MRL is an estimate of the acceptable daily exposure 
level that would not likely result in adverse effects.  
The toxicological data provide insights into the levels of exposure that can cause developmental 
disorders in rats. However, it is essential to understand the pathogenesis of the disorders to fully 


































4 d 500  1000 Decreased testes 
weight 







6 d   500 Decreased testes 
weight 



















9 d   2000 Sever testicular 
atrophy, decreased 
testes weight 






7 d   2100 Decreased testes 










7 d   2400 Decreased testes 
weight 







9 d  2000  Moderate testicular 
atrophy 







7 d   2000 Severe testicular 
atrophy, decreased 
teste weight 











aLess serious = minor growth and development effects that would not affect overall health and fertility. 



























Serious Observations Reference 
Rat 
(Wistar) 
Gd 7-15 500  630 Decreased fetal body weight, 
post implantation loss 





Gd 7-9   750 Decreased fetal body weight, 
post implantation loss, 
skeletal malformations, 
decreased live births per 
litter 















Gd 0-8 250 500 750 Decreased fetal body weight, 
post implantation loss, 
altered sex ratios, decreased 
live births per litter 





Gd 15-17   500 Increased incidence of 
undescended testes, 
reductions in AGD 






Gd 16-19   500 Increased incidence of 
retained nipples, reductions 
in AGD, decrease in volume 
of androgen dependant 
tissues 






Gd 12-21 50 100 250 Decreased AGD, small sex 
accessory glands, decreased 
testes weight, malformations 
of the reproductive tract.  







Gd 12-21  100 500 Malformations of the 
epididymis, decreased AGD, 
retained nipples 









  500 Increased incidence of 
retained nipples, reductions 
in AGD, decrease in volume 
of androgen dependant 
tissues 











Gd = Gestational day 
Ld = Lactation day 
 
Table 2.1: The Toxicological data of oral prenatal exposure to DBP. The response to DBP is far more sensitive with 
serious LOAELs well below the NOEAL of postnatal exposure. 
 
Table 2: The Toxicology studies of effects of oral prenatal exposure to DBP. The response to DBP is far more sensitive 
with serious LOAELs well below the NOEAL of postnatal exposure. 







Serious Observations Reference 
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1.4 Developmental Toxicity 
Developmental toxicity is defined as the teratogenic effects following in utero exposure to 
developmental toxins. Research into the developmental toxicity of DBP has primarily been focused 
postnatal physical effects following embryological exposure of rats and mice. 
The male reproductive system is particularly sensitive to DBP and its primary metabolite monobutyl 
phthalate (MBP,33 see Chapter 4). DBP appears to exhibit toxicity during key stages of male sexual 
differentiation (e.g. during decent of the testes and external genital formation) in rats, producing a 
range of diverse reproductive malformations in a dose dependant manner.32  Such effects are likely 
extrapolatable to other species, including humans. The most common developmental effects are 
decreases in AGD,32 hypospadias (defect of the penis)34 and cryptorchidism (undescended testes,35 see 
below). These developmental disorders are highly typical of the observations following embryological 
exposure to androgen receptor (AR) antagonists (e.g. flutamide),36-38 17β-estradiol (E2) and 
xenoestrogens (e.g. BPA).39,40   
1.4.1 AGD 
The AGD (the distance from the anus to the base of the scrotum or vagina) is sexually dimorphic, with 
healthy males exhibiting an AGD twice that of a healthy female.41 AGD is a good marker of feminization 
and reproductive health as is particularly sensitive to the effects of anti-androgenic compounds and 
xenoestrogens. Exposure to DBP above the NOAEL (250 mg/kg bw/day) during the late stages of the rat 
prenatal period (when sexual differentiation occurs) has been shown to cause a dose-dependent 
decrease in AGD.32 Higher doses (500 mg/kg/day) cause a considerably larger dose response, with AGDs 
24% shorter than non-exposure control groups.32 
The consensus among the many studies of the effects of DBP on AGD is a dose-dependent decrease 
comparable to effects seen following exposure to anti-androgenic compounds or xenoestrogens (see 
Section 1.5.1). The effects of DBP on the embryological development of the external genitalia, including 
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the anogenital region is unsurprising as the development of these tissues is regulated by the androgenic 
hormones (e.g. testosterone and dihydrotestoserone, DHT).42 
1.4.2 Hypospadias and Cryptorchidism 
Hypospadias and cryptorchidism are developmental disorders of the external genitalia. These disorders 
are a commonly observed in animals following embryological exposure to EDCs including DBP. 
Hypospadias is a malformation of the penis where the opening of the urethra is misplaced.34 
Cryptorchidism is where one or both testes fail to descend into the scrotum.35 The pathogenesis of 
these disorders is not completely understood, however, the formation of the external genitalia is 
dependent testosterone (see Chapter 2).  Therefore, exposure to EDCs such as DBP (i.e. reductions in 
gestational testosterone synthesis) may play a role in disease pathology of hypospadias and 
cryptorchidism43 as the incidences of these disorders has increased over recent years,44 coinciding with 
proliferation of environmental EDCs.45 
High embryological exposure to DBP (500 mg/kg bw/day) in rats has been shown to increase the 
incidence of hypospadias. At 500 mg/kg bw/day the incidence was reported at approximately 7% across 
10 individual litters.34 There is a dose response relationship; exposure levels of 750 mg/kg bw/day 
produced litters with incidences of hypospadias ranging from 41-46%.34,35 Serum testosterone levels of 
the rats in these exposure groups follow a similar dose response. As exposure levels increase, serum 
testosterone concentrations decrease linearly; particularly in the offspring with hypospadias which all 
had a significantly lower level of testosterone.35 The natural incidence of hypospadias in rats is not 
known but in humans it has been established at 1 in 125 live births or 0.8%.43 Therefore, if it is assumed 
that the incidence of hypospadias is the same between rats and humans, exposure to 500 mg DBP/kg 
bw/day increased the incidence 9-fold to 9 in 125 live rat births. At 750 mg/kg bw/day the incidence is 
51-58 in 125 live births, over a 50-fold increase. The decline in serum testosterone coupled with 
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significant increases in male sexual development again point to mechanism by which DBP is diminishing 
testosterone production. 
Cryptorchidism follows a similar trend to hypospadias but appears to exhibit a more sensitive dose 
response to DBP at lower exposure levels. Cryptorchidism was observed in rats following orally 
administered DBP at 250, 500 and 750 mg/kg bw/day, with increased incidences of 3.1%, 10.2% and 
45.7% respectively.35 This is again demonstrates the anti-androgenic effects of DBP during embryonic 
development. One United Kingdom study has the rate of incidence of humans at 1 in 125 live births.46 
Again, if we assume the incidences of rats and humans are the same, DBP exposure increased the 
incidences 4, 13, 57-fold at exposures levels of 250, 500 and 750 mg/kg bw/day respectively. 
There is a clear association between increases in incidence of hypospadias and cryptorchidism with 
reductions in testosterone following gestational exposure to high levels of DBP. To date, there are no 
published data on the effect of DBP on hypospadias, cryptorchidism or testosterone levels at normal 
population exposure levels of humans. However, as DBP exhibits a dose-dependent reduction in 
testosterone, it can be assumed that at human daily exposure levels there could be slight decreases in 
testosterone synthesis. Therefore, there is potential for malformations such as hypospadias and 
cryptorchidism to occur from DBP exposure in the normal population. Hypospadias and cryptorchidism 
are easily treatable with surgery and hence are considered the less damaging effects of DBP exposure. 
There are more severe effects which can lead to permanent and destructive reproductive 
malformations (e.g. testicular dysgenesis syndrome, TDS). 
1.4.3 TDS 
TDS is the abnormal growth and development of the two key reproductively active cells of the testes, 
Sertoli (gamete producing) and Leydig (androgen hormone producing) cells.47 The clinical manifestations 
occur during gestation and include: decreased testes weight, abnormal cell hyperplasia and poorly 
27 
  
developed seminiferous tubules (the region where meiosis occurs).47 While the malformations occur 
during gestation, the damaging effects are more observable during puberty and adult life; particularly 
the localized and permanent damage to the testes and infertility.47  
Rats exposed to 500 mg DBP/kg bw/day47 and 750 mg DBP/kg bw/day34 produced offspring with a 20% 
reduction in testes weight at birth compared to controls. Infertility was also prevalent among the DBP-
exposed cohort, with 80% of the F1 males unable to reproduce.34,47 The reductions in testes weight 
became more apparent over time. After 4 days the exposed rats had 45% decreased weight compared 
with control groups.47 Accompanying the reduced testes weight was Leydig cell hyperplasia and 
abnormal seminiferous tubule structure.6 Histological analysis of the testes in DBP-exposed males 
demonstrated Leydig cell clumping and abnormal distribution. As Leydig cells are responsible for 
healthy  development of the seminiferous tubules (see Chapter 2) in utero, the abnormal Leydig cell 
activity likely disrupts the formation of the tubules.47 The disruption in seminiferous tubule formation 
directly leads to reduced Sertoli and germ cell maturation (testosterone is essential for gamete 
production in males). This likely accounts for the reduction in testes weight and infertility following DBP 
exposure in rats.48 
1.4.4 Effects in Humans  
The effects of DBP in utero are ethically challenging to measure in humans and so perhaps the only way 
forward is to extrapolate from animal studies and rely on isolated human case studies. One such case 
relates to the New Zealand Malayan veterans (1950-60) who used DBP to paint the seams of their 
uniforms to prevent infections from trombiculid mites20 (see Section 1.2.1). Estimations based on 
dermal absorption through the skin determined they were exposed to DBP at 64 mg/kg bw/day20 (above 
the MRL and LOAEL). The offspring of the exposed soldiers have a higher incidence of hypospadias and 
cryptorchidism compared to the average age match control in New Zealand, 5.1% and 2.4% 
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respectively.20 The authors of the study postulated that the high DBP exposure of the fathers induced a 
transgenerational toxicological effect via an epigenetic mechanism (see section 1.5.3).20 
A link between clinical manifestations of DBP (and other anti-androgenic compounds) and levels of 
urinary phthalate metabolites has been postulated.49 In a cohort of 134 boys aged 2-36 months, 10 boys 
had high levels of phthalate metabolites, 9 of whom had reductions in AGD. Conversely, 11 boys had no 
phthalate metabolites detected in their urine, with only one exhibiting any reductions in AGD.49 The 
reliability of AGD as a measurement of phthalate induced feminisation in humans remains a contentious 
issue. However, considering the dose-dependent manner in which DBP reduces AGD in animals, there is 
a possibility that DBP does play a role in the feminization of humans. 
There has been a significant rise of precocious (early) puberty among girls in the developed world50 with 
exposure to EDCs being considered to play a significant role.51  The literature on the role of phthalates in 
precocious puberty is conflicting. One study linked phthalates and premature breast development. High 
phthalate levels were detected in 68% of the girls with premature breast development.52  However, 
subsequent studies found no association between phthalates and any signs of precocious puberty (e.g. 
early breast development and pubic hair growth),53 and conversely linked the delay onset of pubic hair 
growth to urinary phthalate metabolite levels in some girls.53  
There is a consensus that DBP toxicity has anti-androgenic like toxicity in utero. While these effects are 
well known and studied, the mechanism of toxicity is still an area of conjecture. 
1.5 Potential Mechanisms of Toxicity of DBP 
The mechanism of toxicity of DBP in humans has yet to be fully established. Several different 
mechanisms have been proposed to explain the anti-androgenic effects; particularly reduced 
testosterone synthesis, which is likely to be responsible for the observed developmental toxicity in 
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animals. The developmental disorders (e.g. hypospadias, cryptorchidism, TDS) are common 
observations following exposure to AR antagonists and xenoestrogens. However, reductions in 
testosterone could occur through a variety of mechanisms that do not affect the hormonal nuclear 
receptors; namely gene regulation or epigenome modification.    
1.5.1 AR Antagonism Xenoestrogenic Activity 
During the 20th century, a plethora of man-made chemicals were introduced and began leeching into 
the environment. These compounds, when absorbed into a higher order organism (including humans) 
have the potential to affect the sexual growth through a mechanism of molecular mimicry (Fig. 1.3). 
Structural analogies to natural steroid hormones leads to uptake of these compounds into cells and 
binding to nuclear receptors. This can change the expression of key genes in human sexual 
development. This often leads to a disruption of the androgen:estrogen ratio. There are two distinct 










Figure 1.3: The molecular mimicry of E2 (black) and Diethylstilbestrol (grey), a known xenoestrogen. There is 
strong structural homology with Diethylstilbestrol having the hydrophobic backbone and hydroxyl functional 





xenoestrogens, compounds that mimic the female sex hormone E2 and bind to and activate the 
estrogen receptor (ER) and AR antagonists which competitively bind to the AR. 
1.5.1.2 Xenoestrogenicity 
Compounds that mimic the structure of E2 in humans are known as xenostrogens (xeno = foreign). 
Xenoestrogens are commonly produced by plants (i.e. phytoestrogens, e.g. 8-prenylnarigenin) or man-
made (e.g. BPA). These compounds share structural similarities with E2 which allows them to fit into the 
hydrophobic binding pocket of the receptor, bind to the key residues and activate the estrogenic 
response.55,56 The exposure of multiple xenoestrogens has been linked to precocious puberty in 
females,57 reduced sperm counts58 and feminizing developmental effects in men (e.g. hypospadias and 
cryptorchidism).43,59 All of these effects have been linked to DBP exposure. An increase expression of 
estrogenic growth factors via activity of DBP could explain the observed developmental effects in males. 
However, there is conflicting evidence for the estrogenic activity of DBP. As mentioned previously, there 
are some data that demonstrate the role of DBP in inducing developmental effects in females (e.g. 
precocious puberty) which could not be explained by anti-testosterone activity alone, but rather an 
increase in estrogenic activity. The estrogenic potential of DBP has been measured using the yeast 
estrogen screen (YES) assay which utilizes genetically modified yeast. The yeast expresses a human ER 
which, upon activation upregulates the expression of β-galactosidase. This enzyme cleaves the yellow 
substrate chlorophenol red-β-D-galactopyranoside (CPRG) which gives a strong red colour. Therefore, 
the estrogenicity of a compound is directly related to the intensity of the red colour in the assay.60 DBP 
has been shown to be weakly estrogenic in this assay with an estrogenic potential 10-5-10-6 less than 
that of E2.61 The YES assay does not account for metabolism of DBP (the yeast lack key xenobiotic 
metabolism enzymes) and hence the estrogenic potential might be higher if the metabolites of DBP 




The developmental toxicity of DBP has strong similarities to AR antagonists.  These compounds bind to 
and inhibit the biochemical functionality of the AR. The AR, much like the ER is a nuclear hormone 
receptor. Upon ligand binding and activation, the AR enters the nucleus and promotes the expression of 
male developmental growth factors.62 AR antagonists competitively bind to the active site of the 
receptor, preventing binding of the natural androgenic steroid hormones. This inhibits activation of the 
receptor and hence prevents the development of healthy androgenic tissues. The effect of exposure to 
these compounds (e.g. vinclozolin) is remarkably similar to DBP exposure. Therefore, anti-androgenicity 
is a possible mechanism of toxicity. 
The evidence, however, does not support DBP being an AR antagonist. While the effects of DBP 
exposure closely resemble the effects of exposure to an AR antagonists there are some key differences. 
The effects of DBP exposure appear to affect tissues not directly related to AR activity. This can be 
observed in the morphological differences in cryptorchidism. DBP appears only to affect the early stages 
of testes decent, (see Chapter 2 for a detailed explanation) which leads to transabdominal testes. AR 
antagonists affect the later developmental stages; particularly the AR-dependant stage inguinal ( i.e. in 
the teste duct) descent of testes.27 Prostate development is completely dependent on AR activation and 
embryological exposure to AR antagonists often leads to an absence of or poorly developed prostate in 
the male offspring.27 However, the prostate is insensitive to DBP exposure, even at high exposure 
levels.27 This is likely due to DBP having little binding affinity for the AR.63,64 A recombinant AR binding 
affinity assay found DBP to have a 10,000-fold lower dissociation constant (the molarity at which there 
is equal amounts of bound and unbound receptor) of 8.2 X 10-4 M compared to 1.8 X 10-8 M  for DHT (the 
natural substrate).64 This demonstrates that DBP only very weakly binds to the AR. However, the assay 
does not account for the metabolism of DBP; therefore, there is the possibility of in vivo metabolites 
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having stronger binding affinity to the AR than DBP. Overall, the evidence is strongly against DBP being 
an AR antagonist. 
1.5.2 Gene regulation  
The nature of the toxic effects of DBP suggest that reductions in the biosynthesis of testosterone plays a 
major role; i.e. all the toxic effects are known to be caused by reductions in testosterone levels in utero. 
The biosynthetic pathway responsible for the synthesis of the steroid hormones is known as 
steroidogenesis.65 The pathway has multiple branches (Fig. 1.4) and produces the estrogens, androgens 
and glucocorticoids (stress hormones). Steroidogenesis is under strict genetic control, with the flux 
changing in response to external stimuli and possibly through effects of EDCs including DBP (for a 




Figure 1.4: The steroidogenesis pathway (asterisks denote multiple steps).  There are three main products: the 
glucocorticoids (e.g. cortisol, green) regulated by the expression of cyp21a1 and cyp11b2, the androgens (e.g. 
testosterone, blue) regulated by hsdb3 and hsd17b3 and the estrogens (e.g. E2, red) metabolised  from 
testosterone under control of cyp19a1. 
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Steroidogenesis begins with cholesterol uptake into the cell via the transporter, steroidogenic acute 
regulatory protein (StAR).66 Cholesterol is then converted into different products under the control of 
several key genes which regulate the flux of the pathway such as: 11β-hydroxysteroid dehydrogenase 
(cyp11b1) and steroid 21-hydroxylase (cyp21a1) for the glucocorticoids, 3β-Hydroxysteroid 
dehydrogenase (hsdb3) and 17β-Hydroxysteroid dehydrogenase (hsd17b3) for the androgens and 
aromatase (cyp19a1) for the estrogens.65 Changes in expression of these genes could lead to major 
changes in the flux of the pathway, leading to a disruption of the steroids metabolism. Therefore, it is 
highly possible that a change in gene expression could occur following DBP exposure, leading to 
diminished testosterone production. 
Exposure to DBP at normal population daily exposure levels has been shown to increase cortisol 
production in R2C cells (Leydig cell line). R2C cells have limited expression of the glucocorticoid genes.67 
Therefore, the irregular cortisol production is indicative of a change in flux of the steroidogenesis 
pathway whereby glucocorticoid synthesis is favoured over androgen production. This could occur 
through a down-regulation of hsd17b3 and/or the up-regulation of cyp11b1. An in vivo postnatal rat 
study found linear increases of cyp11b1 in homogenates of the testes in relation to increasing DBP 
exposure correlating with a linear decrease in serum testosterone levels and increases of serum 
glucocorticoids.68 Western blot analysis found that the glucocorticoid receptor (Gr) protein also had a 
significant increase in expression, demonstrating that exposure to high levels of DBP affects the 
genomics, proteomics and metabolomics of glucocorticoid synthesis. A significant decrease in the 
expression of the gene that codes for StAR was observable following exposures of 1000-2000 mg 
DBP/kg bw/day (the typical LOAEL).68 Continuous StAR expression is required for the steroidogenesis 
pathway to function effectively. Reductions in StAR protein expression could significantly reduce the 
capacity of the pathway to produce steroids.  
34 
  
Glucocorticoids do not have a role in sex differentiation and so an overexpression of the glucocorticoids 
at the expense of testosterone could account for the anti-androgenic like effects of DBP exposure. If 
testosterone and DHT (which control sexual differentiation in utero) levels are diminished there could 
potentially be a disruption of the sensitive androgen:estrogen balance.  
Changes in the expression of the intermediate genes could play a role in the reductions in testosterone 
by limiting the overall steroidogenic capacity of the pathway. Reductions in the expression of the genes 
that code for the cholesterol side-cleavage enzyme (P450scc)), 17α-hydroxylase (CYP17) and StAR were 
observed along with an increase of AR expression and large reductions of serum testosterone levels 
following embryological exposure at 500 mg DBP/kg bw/day,.69 P450scc and CYP17 are important initial 
intermediates, although they do not regulate the flux of the pathway.69 Increases in AR expression is 
likely not in response to AR stimulation but rather a scavenger mechanism in response to drastically 
lower testosterone levels. This has been demonstrated in prostate cells following exposure to the 
xenoestrogen, BPA.70 
The final steps in androgen biosynthesis are regulated by three genes, hsd3b, hsd17b3 and 5α-
reductase. The last step in androgen synthesis is the production of DHT from testosterone by 5α-
reductase. Embryological exposure to 500 mg DBP/kg bw/day has been shown to induce a 2-fold 
decrease in the gene expression of hsd3b. Embryonic exposures of 500 and 700 mg DBP/kg bw/day 
leads to significant decreases in the gene expression and protein synthesis 5α-reductase.71 Male sexual 
development is dependent on the expression of testosterone and DHT in utero. Reductions in the 
expression of hsd3b and 5α-reductase could reduce the capacity of Leydig cells to produce adequate 
testosterone.  
Interestingly, the gene and protein expression of ERα has been shown to increase following exposure to 
DBP.71 Increases in expression of ERs are usually in response to estrogenic activity. Therefore, DBP could 
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be acting as a xenoestrogen.  The increased synthesis of E2 via an increase in expression of cyp19a1 
could account for an increase in ERα synthesis (i.e. Testosterone is being converted to E2). To date there 
are no major studies published regarding cyp19a1 up-regualtion in response to DBP exposure. 
The consensus among the gene expression studies is that the steroidogenic pathway is particularly 
sensitive to DBP exposure in utero with multiple changes in expression of key genes. Overall, the gene 
expression changes likely affect the steroidogenic potential of Leydig cells; particularly through the 
reductions in expression of the key genes responsible for testosterone and DHT synthesis.   
1.5.3 Epigenome modification 
The epigenome is superimposed on the coding regions of DNA and contains regions of heritable genetic 
information, sensitive to behavioural and environmental influence.72 The epigenetic modifications occur 
through chemical changes to cytosine bases and to histone proteins (proteins that package and order 
DNA in the nucleus). These modifications can alter the overall accessibility and structure of DNA, 
allowing for a wide array of genomic states that differ among tissues, developmental and disease 
states.73-75 Cytosine modifications typically occur as methylations on the accessible backbone of DNA via 
action by DNA methyl transferase. These modifications are thought to be a mechanism of heritable 
promotor silences in response to the environment.73 Histone modifications are more complex and 
typically occur at the tail of the protein, which is more unstructured and accessible. There are other 
common chemical modifications; e.g. phosphorylation (serine and threonine),76 acetylation (lysine)77,78 
and methylation (lysine and arginine).79 Epigenetic changes are non-permanent, non-coding 
modifications of DNA that are inherited by several generations via the modification of the parents’ 
gametes.80 
The toxicology of DBP suggests a transgenerational mechanism whereby individuals exhibit the toxic 
effects of DBP without having been exposed.20 This may occur through modifications of the promotor 
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regions of the AR or, via changes in the region that expresses male growth factors (e.g. the androgen 
tissue dependant protein, Insulin-like factor 3, INSL3).  
The transgenerational toxicity of DBP has been observed in the fourth generation of rats (F3).81 The first 
generation (F0) had in utero exposure with expected developmental effects (e.g. TDS, hypospadias). 
These effects continued into the F1-F3 generations in much higher incidence compared with controls.
81 
Analysis of DNA epimutations (methylations) found 197 unique modifications compared with controls.81 
Epigenetic transgenerational effects of DBP have been linked to high level human exposure of the F0 
generation.20 The male offspring of the New Zealand Malayan Veterans (see Section 1.4.4) appear to 
have inherited epigenetic toxicity as the rate of incidence of DBP-like toxic effects in their male offspring 
is nearly 5-fold higher than the general population.20  However, no epimutational studies have been 
conducted on the veterans to date. 
The epigenetic toxicology of DBP is clearly demonstrated in animals and is thought to have occurred in 
one human case example. The overall picture of the mechanism of toxicity appears to occur through a 
range of different mechanisms that combine to reduce potential of Leydig cells to synthesize adequate 
testosterone during key stages in embryonic development. A combination of epigenetic, genomic and 





1.6 Research Aims 
The aim of the present study is to examine two potential mechanisms of toxicity of DBP; namely gene 
regulation and estrogenicity utilizing a rat Leydig cell line (LC-540). This will be achieved via the 
following research goals: 
 Develop the LC-540 culture procedure to maintain robust, long term cultures. 
 Evaluate the suitability of the LC-540 cell line as a toxicological model (e.g. testosterone 
production). 
 Determine the appropriate levels of DBP exposure to best evaluate the effects that could 
feasibly occur in normal human populations. 
 Investigate the effects of these exposure levels on the Leydig cell growth and appearance. 
 Identify any possible estrogenic metabolites and model their analogy with E2 in the ER using 
ChemBio 3D. 
 Determine the metabolism of DBP in LC-540 cells over 24 hours using HPLC. 
 Investigate the potential estrogenicity of DBP in a MCF-7 proliferation assay. 
 Investigate the gene regulatory effects of DBP using the NanoString nCounter assay. 
 Evaluate the effects of the gene regulation on the production of testosterone using a 







1.7 Materials  
1.7.1 Chemicals 
  Dibutyl phthalate (Sigma-Aldrich New Zealand Ltd, Manukau City, New Zealand) 
 Analytical Grade Ethanol (ECP ltd, Auckland, New Zealand) 
 Analytical Grade Acetonitrile (ECP ltd, Auckland, New Zealand) 
 Analytical Grade Diethyl ether (ECP ltd, Auckland, New Zealand) 
 Milli Q water  
  Benzyl penicillin (Sigma-Aldrich New Zealand Ltd)  
  Streptomycin sulphate (Sigma-Aldrich New Zealand Ltd) 
 Sodium Bicarbonate (NaHCO3, (ECP ltd, Auckland, New Zealand) 
 Sodium Sulphate (NaSO4, ECP ltd) 
 L-glutamine (Sigma-Aldrich New Zealand Ltd) 
 Ethylenediaminetetraacetic acid (EDTA, ECP ltd) 
  Ground dextran coated charcoal (Sigma-Aldrich New Zealand Ltd)  
 Magnesium Chloride Hexahydrate (MgCl2.(H2O)6, ECP ltd) 
 Sucrose (ECP ltd) 
 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, ECP ltd) 
  Trypan blue (Sigma-Aldrich New Zealand Ltd) 
 Β-Mercaptoethanol (ECP ltd) 
 Sodium Dihydrogen Phosphate Dihydrate (NaH2PO4.2H2O, ECP ltd) 
 Disodium Hydrogen Phosphate (Na2HPO4, ECP ltd) 
 Sodium Chloride (NaCl, ECP ltd) 
 Thiomersal (ECP ltd) 
 Inert N2 Gas 
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1.7.2 Biological products 
 Phenol red-free MEM powder (Sigma-Aldrich New Zealand Ltd 
 Phosphate buffered saline (Sigma-Aldrich New Zealand Ltd)  
  Fetal bovine serum (Life Technologies, Auckland, New Zealand; Catalogue number 10091-148) 
 Trypsin powder (Becton Dickinson, Auckland, New Zealand) 
 TrpLE® express (Life technologies) 
 LC-540 rat Leydig cells (American Type Culture Collection (ATCC), Manassas, USA; ATCC number 
CCL-43) 
 MCF-7 human breast cancer cells (American Type Culture Collection (ATCC), Manassas, USA; 
ATCC number HTB22) 
 RNeasy Lysis Buffer (RTL) 
 Bovine Serum Albumin (BSA) 
 Testosterone Antibody (Canterbury Health Laboratories, CHL)  
1.7.3 Equipment 
 T-75 sterile culture flask (Sigma-Aldrich New Zealand Ltd)  
 10 μL Hamilton Syringe ((Sigma-Aldrich New Zealand Ltd)) 
 Glass Vials (4 mL, 7 mL, 20 mL) 
 Eppendorf tubes (100 μL, 600 μL, 1.6 mL) 
 50 mL Centrifuge tubes 
 Automatic pipette and Tips (10 μL, 100 μL, 1 mL)  
 Sterile filter (Steritop-GP, 0.22 μm, polyethersulfone, 500 mL 45 mm Merck Millipore) 
 Autoclave 
 Laminar flow cabinet (Cytoguard CG2000 series, model CGA-180, Clyde Apac, Sydney, Australia)  
 Inverted microscope (CKX41, Olympus, Melbourne, Australia)  
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 Microscope camera (Toup ltd) 
 Toup camera software (Toup ltd) 
 Haemocytometer 
 Periplast plastic counting chamber (Thermo Fisher Scientific, Melbourne, Australia) 
 Non sterile syringe filter (7.5mm non-sterile PTFE hydrophobic filter, Thermo Fisher Scientific, 
Melbourne, Australia) 
 Centrifuge (multifuge 1 S-R, Heraeus, Hanau, Germany) 
 Glassware (Separation funnel, Round bottom Flask, conical flask) 
 Hot-plate stirrer 
 Micro well  plates (24, 96 wells) 
 Schott bottles (100 mL, 500 mL, 1000 mL) 
 HPLC (Dionex) 
 C18 reverse Phase HPLC column (Phenomex, North Shore City, New Zealand)  
 gDNA removal column 
 nCounter cartridge (NanoString Technologies®, Seattle, WA) 
 Custom nCounter CodeSet (reporter and capture probes, (NanoString Technologies®, Seattle, 
WA) 
 GEN2 Digital Analyzer (NanoString Technologies®, Seattle, WA) 

















2.1.1 The Testes 
The role of the testes in male fertility and physical development has been known since ancient times; 
particularly by Aristotle who noted the effects of male castration in 300 BC.82 The testes are the 
reproductive organs of male mammals, responsible for the production of the androgenic hormones via 
steroidogenesis in Leydig cells and production of gametes through spermatogenesis in Sertoli cells.83 
The testes are paired organs structurally surrounded by two layers of connective tissue; namely the 
tunicia vaginalis and tunica albuginea, the latter of which evaginates to divide the testes into several 
hundred lobules. Within these lobules, spermatogenesis occurs inside the densely coiled seminiferous 
tubules which comprise the bulk of the testes. The immature sperm cells that develope in the 
seminiferous tubules are transported to the epididymis where they mature into reproductively active 
gametes. During ejaculation, the gametes are pushed by muscle contraction through the epididymis and 
transported out of the testes via the ductus deferens. The production of androgenic hormones occurs in 
the testes independently of spermatogenesis in Leydig cells through a complex multiproduct 
biochemical pathway (see Section 5.1.3). 
2.1.2 A brief history of Leydig Cells 
Franz von Leydig first characterized Leydig cells in the testes in 1850.84 Leydig extensively studied the 
testes of many species, observing that small clusters of cells were consistently collected between the 
seminiferous tubules.84 Leydig postulated the role of these cells as simply connective tissue. Other 
prominent researchers incorrectly believed Leydig cells to either be immature Sertoli cells or associated 
with lymphatic vessels and embryonic epithelial cells.86 The consensus in the late 19th century was that 
Leydig cells aid spermatogenesis by providing energy to seminiferous tubules via metabolism of plasma 
nutrients (e.g. glucose).86 Unsurprisingly, the prominent researchers at the time did not associate Leydig 
cells with endocrine functionality as the endocrine system as a whole was poorly understood. However, 
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between 1897 and 1905 Pol Bouin and Paul Ancel published four key articles explicitly linking Leydig 
cells and their endocrine functionality to controlling secondary sexual characteristics in males.87 The key 
findings of their research were:  
1. Leydig cells have the appearance of secretory cells (i.e. features of endocrine functionality).  
2. Leydig cells are present in large numbers during key stages of embryonic development (i.e. likely 
to play a role in fetal development). 
3. Leydig cells do not supply nutrients to the seminiferous tubules.  
 
The first biochemical evidence for testosterone production in Leydig cells was published by Christensen 
and Mason.88  Their research demonstrated the bioconversion of [14C]-progesterone into [14C]-
androstenedione and [14C]-testosterone in interstitial tissue isolated from rat testes. This proved 
unequivocally that Leydig cells, not Sertoli cells are responsible for the production of testosterone and 
are the primary factor that influence sexual growth and development of the male phenotype. 
2.1.3. Fetal  Leydig cells (FLCs) 
Leydig cells are comprised of two distinct morphologies; namely fetal Leydig cells (FLCs) and adult 
Leydig cells (ALCs, see Section 2.1.4). The morphologies have differing functionalities which account for 
their diverse ultrastructural, topographic and biochemical properties. However, ALCs and FLCs are both 
essential in healthy male sexual growth and development from embryo and throughout adulthood. 




FLCs develop in utero during weeks 7-8 of human pregnancies directly after the development of the 
testis cord. FLCs are essential during male embryonic differentiation; particularly in regulating the 
development of the Wolffian duct (the structures that form the male internal genitalia), external 
genitalia and testis descent. 
2.1.3.1 Morphology of FLCs 
Histological analysis has shown that FLCs typically form large clusters of oval shaped cells between 
seminiferous tubules. These clusters are in turn surrounded by a thin layer of fibryocytes and collagen 
between the individual FLCs of a cluster.89 Human FLCs vary in size and shape, with some cells being 
small and circular with enclosed organelles, while others are larger, polyhedral shaped with less 
delimited nuclei and cytoplasm (i.e. less defined organelle boundaries).90  
The ultrastructural features of FLCs have been elucidated by electron microscopy.89 FLCs have round or 
oval shaped nuclei dense with chromatin and a central nucleolus. The cytoplasm contains an abundance 
of smooth endoplasmic reticulum (SER), mitochondria, membrane bound lysosomes and large lipid 
droplets (average diameter 0.9 μm).89  There is a lack of rough endoplasmic reticulum (REM) and the 
Golgi apparatus is small. The function of SEM in part is the metabolism of lipids.92 Therefore, the 
abundance of SER and the lack of REM are unsurprising as the key function of FLCs is to produce the 
steroid hormones (i.e. they are lipids). Therefore, an abundance of SEM is necessary for FLC function. 
The small size of the Golgi apparatus may be due to the lack of REM as the two organelles are closely 
related.92 The surfaces of FLCs have very characteristic flat, polyhedral cytoskeletal protrusions. The 
clusters of FLCs are completely surrounded by the basal lamina which acts as connective tissue to fix the 
cell clusters between the seminiferous tubules. 
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2.1.3.2 Function of FLCs 
FLCs produce a wide range of biologically active molecules and peptide hormones. The primary products 
(common to all Leydig cells) are the androgenic hormones, which are essential for healthy male sexual 
development during embryonic development; particularly the development of the Wollfian duct, 
external genitalia and the descent of the testis.93 
The Wolffian ducts are the embryonic structures that develop in utero to form the male internal 
genitalia. The production of testosterone and DHT by FLCs plays a major role in the healthy 
development of Wolffian ducts. In humans, at approximately 7 weeks gestation, the Wolffian ducts 
form independently of FLCs and androgen hormones.94 The FLCs develop shortly afterwards and begin 
excreting androgen hormones.95 These hormones travel to the newly developed Wolffian ducts. The 
androgens bind to the highly expressed ARs in the cells of the Wolffian duct tissue, upregulating specific 
growth factor proteins which grow and differentiate the Wolffian ducts into several adjacent structures 
of the internal reproductive system; namely the epididymis, vas deferens and seminal vesicles (see 
below for a detailed explanation).95 The external genitalia, the penis and urethra develop between 
weeks 11-24 of gestation96 and their development is completely dependent of androgen hormones. 
Expression of AR is increased in the penile glans and the urethral epithelial cells of the embryonic 
genitalia. Testosterone and DHT bind to ARs to up-regulate the production of growth factor proteins, 
developing the penis by week 24 of gestation.96 
FLCs also produce INSL3, a small peptide hormone which regulates testes descent. This process is 
essential for male fertility (i.e. spermatogenesis requires a lower temperature than the internal 
temperature of the human body). Testes descent is a two-phase process beginning approximately 10 
weeks gestation in humans. The transabdominal phase and inguino-scrotal phase are regulated by INSL3 
and androgen hormones respectively.97 
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97During early embryonic development, the pre-differentiated gonads develop inside the urogenital 
ridge (a pair of dorsolateral ridges comprised early embryonic germ cells). The gonads are fixed in 
position by two structures: the gubernaculum and the cranial suspensory ligament (CSL).97 The growth 
or recession of these ligaments is sexually dimorphic and regulated by different hormones in males and 
females. In males, the CSL must regress to initiate testes decent. The transabominal phase of testes 
descent begins shortly after Wolffian duct differentiation. This phase involves the regression of the CSL 
and elongation of the gubernaculum (a cord made of fibrous tissue that connects the fetal testes to the 
base of the scrotum) to penetrate the scrotum, forming the inguinal canal (the path that the testes 
descend into the scrotum). This process is regulated by INSL3 binding to and activating to the leucine-
rich Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 8 (LGR8), expressed on the surface of 
the intra-abdominal gubernacular mesenchyme cells.97 The process is cyclic adenosine monophosphate 
(cAMP)-mediated with the activation of kinases inducing hyperplasia and tissue growth of the 
gubernaculum. The growth of the CSL is simultaneously inhibited. This prevents feminization of the 
gonads (i.e. development of the CSL helps fix the ovaries during female growth and development).98 The 
transabdominal phase ends with the testes held close to the newly developed inguinal canal and 
scrotum. The inguinoscrotal phase begins after the completion of the transabdominal phase, beginning 
with the regression of the gubernaculum. 
The inguinoscrotal phase begins at approximately 26 weeks gestation and finishes at 35 weeks after the 
testes enter the scrotum. The entire process is mediated by the androgenic hormones, testosterone and 
DHT.95 The gubernaculum contains high expressed ARs which regulate the entire inguinoscrotal phase.99 
The androgens act as paracrine (cell-cell signalling hormones) factors in the gubernaculum cells and 
initiate regression of the extracellular matrices of the cells. This leads to degradation of the structural 
supporting materials of the cells (e.g. the fibrous proteins).100 This alters the viscoelasticity (the property 
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of both viscosity and elasticity when under pressure or stress) of the gubernaculum such that the 
growth development of the other organs in the body cause intra-abdominal pressure, pushing the 
testes into the inguinal canal.101 
2.1.4 ALCs 
2.1.4.1 ALC morphology 
The development of ALCs is triphasic with three distinct morphologies: neonatal Leydig cells (NNLCs), 
immature Leydig cells (ILCs) and mature ALCs.102  The first four months of the male neonatal period is 
associated with high levels of testosterone produced by NNLCs which are present in high numbers.89 
The NNLCs have a very similar morphology to FLCs (i.e. organelles associated with steroid-producing 
cells); namely an abundance of SER and lipid droplets, localised RER, abundance and variability in size 
and shape of mitochondria.103 The abundance of testosterone-producing Leydig cells after birth is likely 
due to continuing post-natal sexual differentiation of the central nervous system which develops at 
approximately four months post-gestation.104 The presence of testosterone in the serum of males at this 
development period is essential in permanently masculinizing the male phenotype. Testosterone action 
prevents any reversal of sexual differentiation during the first  4 months of the postnatal period.104 
After four months post-gestation, the NNLCs begin to regress into ILCs, the non-androgen hormone 
producing morphology of Leydig cells. ILCs are abundant from four months post-gestation until the late 
stages of puberty.105 ILCs are small round cells that are morphologically distinct from FLCs and NNLCs. 
They have spherical nuclei with irregular membrane shape, more RER, few lipid droplets and a more 
developed Golgi apparatus.105 Immunostaining studies found that ILCs have limited activity of 17β-HSD 
(a key enzyme in testosterone biosynthesis).105 ILCs have a high activity of testosterone-metabolizing 
enzymes (e.g. 3-oxo-5α-steroid 4-dehydrogenases and 3α-hydroxysteroid dehydrogenase). Therefore, 
ILCs have steroidogenic capacity but can only producing limited amounts of testosterone. The 
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testosterone is typically converted into reduced forms of the androgen hormones (likely to prevent 
precocious puberty). The biology of ILCs is perfectly suited to their role of maintain low levels of 
testosterone required for prepubescent boys. 
Fully mature ALCs are responsible for the majority of testosterone production during puberty. ALCs are 
directly responsible for the sexual maturity of males (e.g. maturation of the genitals).  
2.1.4.2 ALC Function 
The primary function of ALCs is to ensure the adequate production of both testosterone and DHT to 
regulate the sexual maturity during puberty (e.g. bone, tissue and hair growth).106 ALCs fully develop at 
puberty and begin to produce and excrete large amounts of testosterone.107 The high concentrations of 
testosterone act on the androgenic tissues throughout the body, initiating growth of the 
musculoskeletal system and development of the secondary sexual characteristics (e.g. deepening voice, 
hair growth). The increase in testosterone levels also affects the testes themselves; particularly the 
maturation of Sertoli cells (i.e. developing the machinery for spermatogenesis). Testosterone 
continuously acts upon the Sertoli cells to produce the gametes.  ALCs are essential throughout adult 
life to maintain and regulate the male tissues and processes (e.g. spermatogenesis).  
2.1.5 Use of Cell Culture to Study Cell function and Biochemistry 
2.1.5.1 The Advantages of Cultured Tumour Cell Lines 
The culture of primary cells (i.e. healthy cells isolated from tissue) is typically difficult to maintain in long 
term culture as they do not readily divide in vitro due to senescence (cellular ageing).108 Therefore, 
primary cells have finite numbers of divisions after which, the cells begin to regress (i.e. lose their 
biochemical functionality) and undergo apoptosis. This is problematic when using cell cultures as a 
model system (a practise common in a variety of fields, from immunology to toxicology).109 Therefore, 
the need to preserve the cells in culture is essential to modern science and so immortalized (cancer) cell 
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lines have been developed for a range of cell types. Immortalization can occur through several 
dysregulations; namely, cell cycle pathway breakdown (e.g. impairment of the signalling of 
p53/p16/pRb tumor suppression proteins), up-regulation of telomerase activity (i.e. elongation of the 
telomeres increases the stability of the chromosome, allowing for greater number of divisions) or by up-
regulation of oncogenes and oncoproteins.110 Many immortalization develop naturally in an organism 
(i.e. oncogenesis) and can be extracted and purified.111 A notable example of this is HeLA cells (a cervical 
cancer cell line extracted from a patient named HEnrietta Lacks) or Jurkat (T lymphocyte cell line 
isolated from a 14 year old boy suffering from T cell leukemia).112 Isolated cancer cells can be further 
modified through the insertion or deletion of specific genes to develop specific pathways or 
impairments (e.g. the D1.1 derivative of Jurkat cells that does not contain surface receptor proteins of 
the parent cell line).113 
Alternatively, viral vectors are often used to artificially induce immortality in cell lines of interest. 
Oncoviruses can be programmed to introduce genes that upregulate telomerase activity or inhibit 
normal cell cycle function.109 Typically, the dysgenesis of cellular signalling or telomere functionality 
initiates a cell crisis; a signalling cascade similar to the cellular responses to DNA damage, resulting in 
apoptosis.114 However, some cells can prevent the cell crisis through silencing of the DNA damage 
pathway (e.g. silencing of tumour suppression genes), producing a cell that escapes cellular 
senescence.115,116 The resulting cells are immortal and can be cloned in culture over long periods 
without regression of growth.  It is important to note that in vitro cultured cells can change over time as 
the cell machinery favours division over other biochemistry, potentially creating a clone that scarcely 
resembles the parent cell phenotype. 
2.1.5.2 Tumour Cell Line Phenotype Changes in Culture 
Tumour cells in culture are known to have genetic instability (i.e. can be affected by numerous genetic 
and epigenetic factors) which can give rise to distinct variants (e.g. karyotypically distinct cells) with a 
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selective advantage (e.g. superior immunological or metabolomic factors).117 A variant with an 
advantage will typically outgrow the parent cell in vitro, a process known as clonal evolution.117 The 
unstable genetic nature of cell lines in vitro allows for spontaneous epigenetic changes that can result in 
biochemical changes of specific cell signalling and functionality (e.g. endocrine cells which require 
external hormones for cellular growth). Such modifications can persist if they are favourable for 
continuous growth. The result of clonal evolution is usually the degradation of cell specific processes 
and direction of metabolic energy towards maximum proliferation efficacy.  
The genomic changes in cell lines has been characterized in hepatic cell lines (BRL3A and NRL clone 9).118 
Hepatic cells are essential in xenobiotic metabolism and utilize a variety of CYP isozymes and 
conjugation enzymes (e.g. glucuronosyltransferases) in Phase I and II metabolism (see Chapter 4 for a 
detailed discussion of xenobiotic metabolism). Microarray analysis of 3984 genes in both cultured 
hepatic cell lines and whole liver found significant (i.e. P > 0.05 and fold change ≤ 10) changes in 
expression of 781 and 714 genes in BRL 3A and NRL clone 9 cells, respectively.118 The genes up-
regulated in the cell lines were those of structural proteins (e.g. proliferin, elastin, crystallin, and 
collagen), proteins involved in growth and differentiation (e.g., galectine, insulin-like growth factor (IGF) 
binding protein and IGF receptor). Conversely, the genes down-regulated were typically enzymes 
involved in Phase I and Phase II metabolism (i.e. CYP isoenzymes. sulfotransferases, and 
glucuronosyltransferases). Western Blot analysis of the two cell lines found no detectable protein levels 
of some CYP isozymes (e.g.  2B, 4A, and 2C11). The down-regulation of xenobiotic metabolism genes in 
the BRL 3A and NRL clone 9 cell lines illustrates the problematic nature of in vitro cultures; i.e. the 
downregulation of specific cellular functionality (BRL 3A and NRL clone 9 cells would be a poor model 
for hepatic degradation of xenobiotics in vitro, as they move away from normal cell function).  
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The surface and nuclear receptors of tumour cells is also highly susceptible to morphological changes in 
vitro; particularly, cell surface receptors involved in suppression of tumours. An analysis of 51 cell lines 
derived from human breast cancers found a wide array of modifications to key nuclear and surface 
receptors.119 Gene expression of ER was negative in 32 of the 51 cell analysed. Western Blot analysis 
found 27 of the cell lines having reduced synthesis of ER. Similarly, the expression of the progesterone 
receptor was also transcriptionally negative in 46 of the 51 cell lines.119 The surface protein human 
epidermal growth factor receptor 2 (HER2, an oncoprotein associated with breast cancer in vivo) was 
found to be expressed in 11 of the 51 cell lines.119 The variety of different expressions of these receptors 
illustrates the differences between cancer cell and the parent cell from which they were derived. 
MCF-7 is a breast cancer cell line commonly used as a model of estrogenecity of xenoestrogens as it is 
known to be ER positive (i.e. positive expression of ER). However, spontaneous epigenetic alterations 
can lead to loss of ER expression in vitro if there is loss of ER signalling. This is a direct result of CpG 
methylation of the ER promotor region of MCF-7 cells.120 The loss of ER transcription likely results in a 
clone which is unresponsive to E2 in culture. The typical culture conditions of MCF-7 cells have limited 
sources of E2. This could lead to a loss of ER signalling and produce a non-ER responsive clone. This 
again illustrates the problematic nature of tumour cell lines; i.e. cell lines are sensitive to factors 
typically only found in culture conditions, potentially altering their biochemical framework in such a way 
that limits their efficacy as model system. These alterations are not always immediately obvious (e.g. 
the loss of ER expression in MCF-7 cells). Therefore, it is essential to ensure that the model system cell 
line ideally has fully intact biochemical machinery.   
2.1.6 Leydig Tumour Cell Lines 
There are several commercial Leydig cell lines available on the market today; particular of rodent origin 
(e.g. R2C, LC-540, MA-10).121 These cell lines are typically naturally occurring neoplastic cells found in 
epithelial tumours of inbred rodents. They are isolated, purified and frozen to be sold for use in 
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scientific research. Human Leydig cell lines have yet to commercially available at the time of publishing 
this thesis. In humans the epithelial neoplasms are rare and slow growing.122 Rodent Leydig cell tumours 
express platelet-derived growth factor (PDGF) in much higher levels than human Leydig cancer cells.123 
Therefore, it can be assumed that the poor growth characteristics of human Leydig cancer cells 
contributes to the lack of commercial availability. 
2.1.6.1 Biochemical Changes in Leydig Cell Lines 
As previously discussed in sections 2.1.2-4, the primary function of Leydig cells is the biosynthesis of 
testosterone to regulate male sexual development. Therefore, in order for a Leydig cell line to be a 
viable model system it must have two key biochemical factors intact: the steroidogenic machinery and 
the endocrine signalling system intact (i.e. the cells steroidogenic regulation). There are many cell lines 
available that have impairments in a one or both of these key systems (e.g. R2C cells).  
A murine cell line, M5480 has been shown to produce detectable quantities of testosterone in vitro 
under basal conditions (e.g. without external activation by a gonadal stimulating hormone such as 
human chorionic gonadotropin, hCG).124 This suggests that M5480 cells have an intact steroidogenesis 
pathway. When cultured in medium containing hCG there is a significant increase in testosterone 
production by M5480 cells. However, over time the M5480 cells begin to form clones which produce 
less androgen hormones in favour of progesterone. These derivatives (M5480A and M5480P) have 
distinct steroidogenic potential; e.g. M5480A produces equal amounts of testosterone and 
progesterone, while M5480P produces far more progesterone that testosterone.124 Similarly, M5480A 
has a far greater binding affinity to hCG than M5480P. Analysis of 5 further derivatives: MA 10, MA 12, 
MA 14, MA 16 and MA 18 found that for three derivatives were unable to bind significant amounts of 
hCG and had limited testosterone production.124 Incidentally, 2 clones were able to be stimulated by 
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hCG, with modest increases in testosterone production. However, these cells tend to produce 20a-
dihydroprogesterone instead of testosterone.  
These data illustrate the potential for Leydig cell lines have reduced expression of the regulatory and 
steroidogenic machinery in long term cultures. 
2.1.6.2 LC-540 cell biochemistry 
LC-540 cells are a Fischer rat Leydig tumour cell line that has been used as a model system for 
investigating the effects of endocrine disruption; particularly the anti-androgenic effects of 
environmental pollutants on steroidogenesis.67,125,126 Unlike other Leydig cell line variants, LC-540 cells 
have minimally impaired steroidogenesis pathway and have been shown to produce testosterone at 
high levels compared with other Leydig cell lines.127 This is in contrast to other Leydig cell lines; namely, 
R2C cells which produce glucocorticoids instead of testosterone.67 
LC-540 cells have been shown to be transplantable into castrated rats in situ and produce detectable 
levels of testosterone. LC-540 cells have an intact steroidogenic pathway that has been demonstrated to 
produce testosterone in vitro for up to 52 passages.128 The amount of testosterone produced without 
external stimulation is approximately 60 pg/106 cells, a 30-fold decrease compared to primary Leydig 
cell cultures.127 Stimulation of LC-540 cells by hCG increases testosterone production slightly over at 48-
72 h.127 Interestingly, compared to primary cultures the response to hCG stimulation is approximately 
100-fold less. Primary cultures can exert the maximum effect of hCG stimulation when only 1% of their 
receptors are occupied by gonadotropins.  In contrast, tumour Leydig cells require 60-80% occupancy of 
the gonadotropin receptors.129,130 This coupled with a reduction (80-90%) of the surface gonadotropin 
receptors,129,130 likely contributes to the significant reduction in steroidogenic potential following hCG 
stimulation. As mentioned above, many Leydig tumour cells produce progesterone instead 
testosterone. This has been attributed to a reduction in CYP17 activity.131 There are no published data 
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on the production of other steroids by LC-540 cells; therefore, it is unknown if they have the same 
deficiency in CYP17 activity. 
2.1.7 The Use of LC-540 Cells as a Toxicological Model 
LC-540s have been used as a model system for investigating the effects of many compounds on 
steroidogenesis and testicular apoptosis.125-127,132-134 The wide array of applications of LC-540s supports 
their acceptance as a model system.  
LC-540 cells have been used to investigate the effects of the pro-inflammatory cytokine tumour necrosis 
factor alpha (TNFα).125,126 The intact steroidogenic pathway allowed for the identification of the 
steroidogenic inhibitory effects of TNFα on the gonads. TNFα was demonstrated to reduce the gene and 
protein synthesis of 17B-HSD, 3β-Hydroxysteroid dehydrogenase (3β-HSD) and StAR.126 Futhermore, the 
inhibitory effects of TNFα on steroidogenic gene regulatory factors; namely histone deacetylases 7 
(HDAC7) were identified.125 Therefore, it can be concluded that LC-540 cells are a good model system 
when investigating the expression of key genes and enzymes involved in steroid biosynthesis as changes 
in these genes following the administration of anti-androgenic compounds are quantifiable.  
The mechanism of luteinizing hormone (LH) action is a cAMP-dependant G-coupled protein receptor 
(GPCR) signalling cascade (see Section 5.1.2). The activity of LH increases cellular cAMP which, in turn, 
increases the activity of cAMP-dependent protein kinase (PKA). Theses kinases activate promotors to 
upregulate the expression of steroidogenic genes.  LC-540 cells have been used to characterize the 
effects of compounds on adenylate cyclase activity. Exposure to tributyltin (an anti-fouling paint used 
on ships) and Gossypol (a terpenoid aldehyde found in plants) was found to inhibit adenylate cyclase 
activity in LC-540 cells in vitro.133,134 These studies demonstrate the viability of LC-540 cells as a model 




The characterization and previous use of LC-540 cells as toxicological models strongly suggest they are 
appropriate for investigating the effects of anti-androgenic like compounds (e.g. DBP) in vitro. 
2.2 Research Aims 
The aim of the research described in this chapter is to develop and evaluate the LC-540 Leydig cell line 
as a model system to investigate the potential mechanisms of toxicity.  
This will be achieved via the following research objectives: 
 Develop a robust cell culture protocol that allows the culture of cells of many generations. 
 Characterize the appearance and growth characteristics off LC-540 cells in culture. 
 Analyse the steroidogenic functionality of LC-540 cells with and without hormonal stimulation 






2.3.1.1 Glassware and Consumables 
All glassware and consumables including Schott bottles, glass pipettes, sample vials, micropipette tips 
and Eppendorf tubes were autoclaved at 120°C, 15 psi for 80 min. All autoclaved equipment was then 
dried at 75°C for 1 h prior to use. 
2.3.1.2 Maintaining an Aseptic work surface 
All cell culture procedures were conducted in a laminar flow cabinet with an internal work surface pre-
sterilised by UV radiation (254 nM, 2 h). Immediately prior to any cell culture work, the internal surface 
was sterilised with 70% v/v ethanol aerosol. All equipment and reagents were sprayed with ethanol 
aerosol and immediately transferred inside the laminar flow cabinet. 
2.3.2 Preparation of Cell Culture Media and Related Reagents 
2.2.2.1 Preparation of Antibiotics 
Benzyl penicillin (3.0 g) and streptomycin sulfate (2.8 g) were added to 100 mL of sterile MilliQ water 
and stirred using a magnetic stirrer for 24 h. The solution was stored at 4°C for up to six months. 
2.3.2.2 Preparation of Phosphate Buffered Saline (PBS) 
A packet of PBS powder was added to a 1 L Schott bottle. Milli Q (900 mL) was added and the PBS 
dissolved via vigorous shaking. The pH was adjusted to 7.4 using 1 M and 0.1 M HCL or NaOH as 
appropriate. The pH adjusted solution was topped up to 1 L with miili Q water. The solution was 
autoclaved and stored at 4°C. 
2.3.2.3 Preparation of Trypsin Protease 
NaCl (8.5 g) was dissolved in MilliQ water (1 L). Trypsin powder (25 g) was added to the 0.85% (w/v aq) 
NaCl (1 L) and stirred (using a magnetic stirrer) at room temperature for 1 h. The trypsin solution was 
sterilised by filtration and dispensed into 10-20 mL aliquots and stored at -20 C. EDTA (3.72 g) was 
dissolved in PBS (1 L) and sterilised by autoclaving. This PBS/EDTA (PE) solution was diluted 10-fold with 
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PBS and 90 mL of the diluted PE was mixed trypsin solution (10 mL) to produce the final trypsin solution 
(2.5% aq). This solution was stored at 4°C for up to 3 weeks. 
2.3.2.4 Heat inactivation of Fetal Bovine serum (FBS) 
FBS (500 mL) was thawed at 4°C overnight. The thawed serum was gently warmed in a 37°C water bath 
for 30 min with gentle inversion every 10 min to ensure even temperature distribution. After the serum 
reached 37°C it was placed in a 56°C water bath for 60 min with gentle inversion every 10 min.  The 
serum was left to rest at room temperature for 30 min. Aliquots (100 mL) were transferred to Schott 
bottles and stored at -20°C. 
2.2.3.5 Preparation of Charcoal-dextran Stripped FBS 
MgCl2(H20)6 (0.3 g), sucrose (85.6 g), 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES, 2.4 g) 
was added to a 1 L Schott bottle.  Milli Q water (1 L) was and the bottle was shaken vigorously. The 
solution was divided into 50 mL aliquots. Two aliquots were added to two 50 mL plastic centrifuge tubes 
each containing dextran coated charcoal (0.137 g).  The centrifuge tubes were inverted 10 times to 
ensure even distribution of charcoal-dextran. The tubes were incubated for 24 h at 4°C. Following 
incubation, the charcoal-dextran solution was centrifuged at 500 xg for 10 min and the supernatant was 
discarded. FBS (50 mL) was added to each pellet. The tubes were inverted 10 times and incubated for a 
further 24 h. The FBS-charcoal solution was then centrifuged at 1700 xg for 10 min and the stripped FBS 
decanted into a 100 mL Schott bottle and stored at -20°C. 
2.3.2.6 Preparation of Phenol Red Free Eagles’ Minimum Essential Medium (MEM) 
Containing 10% v/v Stripped FBS 
Heat Inactivated and charcoal-dextran stripped FBS (100 mL) was thawed at 4°C overnight. Phenol red 
free MEM powder (9.6 g), NaHC03 (2.2 g), L-glutamine (0.292 g) was added to a 1 L Schott bottle. Milli Q 
(800 mL) was added and the powder dissolved via vigorous shaking. The pH was adjusted to 7.4 (see 
section 2.2.2.2) and milliQ (100 mL) was added. FBS (100 mL) and antibiotics (5 mL) were added to the 
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solution. The culture media was then sterilised via ultra-filtration through a 0.22 μM filter and stored at 
4°C. 
2.3.3 Cell Maintenance and Passage 
2.3.3.1 LC-540 Cell Seeding 
A 1 mL cyro-vial containing frozen LC-540 cells was removed from storage in liquid nitrogen (-196°C) and 
thawed at room temperature for 15 min. MEM (20 mL) was added to a sterile 75 cm2 culture flask using 
a flame sterilised 10 mL pipette. The defrosted cell suspension (100 μL) was added to the MEM using a 
micropipette and sterile tip. The cells were incubated at 37°C in 5% v/v CO2 until they reached 
confluence. 
2.3.3.2 Maintenance Cell Culture 
LC-540 cells were routinely passaged when the cultures has reached confluence (approx. 107 cells). 
Spent MEM was vacuum aspirated using a flame sterilised Pasteur pipette. PBS (4 mL) was added to 
inactivate the any residual MEM. TrpLE® express (a proprietary trypsin solution, 3 mL) was added to 
detach the cellular monolayer. The culture flasks were incubated at 37°C with 5% v/v CO2 until cells 
were seen to be fully detached under an inverted microscope. MEM (10 mL) was added to inactivate the 
TrpLE® express and the cell suspension was transferred to a 50 mL centrifuge tube. The suspension was 
centrifuged at 4000 xg for 5 min and the supernatant was vacuum aspirated. The pellet was suspended 
in fresh MEM (10 mL for each new culture) and vortex mixed for 10 s to produce a homogenous 
suspension. Cell suspension (10 mL) was added to a 75 cm2 culture flask containing 10 mL fresh MEM to 
give a total volume of 20 mL. The cells cultures were incubated at 37°C (see 2.3.3.1) 
2.3.4 Cell Counting  
2.3.4.1 Hemocytometer  
A 100 μL sample of cell suspension was collected from a known total volume of cell suspension. 10 μL of 
this suspension was mixed in a 1:1 ratio of trypan blue. A cover slip was placed horizontally across the 
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hemocytometer and 10 μL of the trypan blue-cell suspension was added to each chamber. Each 
chamber was filled with approximately 900 nL of cell suspension. The cells contained in the four 100 nL 
corner grids of both chamber (n=8) were counted using an inverted microscope at 100x magnification.  




 x D x 104               CTotal   CmL x V 
 CmL = Cells per mL  
 CTotal = Total number of cells in the cell suspension 
 T = total number of cells counted in 8 grids 
 k = 8 
 D = dilution factor  
 V = total volume of cell suspension 
2.3.4.2 Periplast® Plastic Counting Chambers 
Periplast® Plastic Counting Chambers were used to count the cells with large number of samples at any 
given time. A 100 μL aliquot from each sample of cell suspension was collected from a known total 
volume and mixed 1:1 with trypan blue. A 9 μL aliquot of each sample was added to the 9 x 9 grids (10 
per chamber).  The same 5 squares were counted for each of the 10 samples under an inverted 
microscope at 100x magnification. The total cell count was calculated from the formulae: 
CmL  
       
     
                   CTotal   CmL x V 
 CmL = Cells per mL  
 CTotal = Total number of cells in the cell suspension  
 T = total number of cells counted 
 k = 0.111  
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 N = 5  
 V = total volume of cell suspension 
2.3.5 LC-540 Growth Curves 
Growth curve measurements were done in triplicate over 10 days.  Confluent cells (3 flasks) were 
removed from incubation and the cells detached using 4 mL of 2.5% trypsin and incubated for 5-10 min. 
Fresh MEM (26 mL) was added. The cells were divided into 1 mL aliquots and added to 1.6 mL 
Eppendorf tubes (n=24). 20 μL was taken from each Eppendorf and the cells counted (see section 2.3.4).  
To normalise the number of cells in each well, the cells were seeded into a 24 well plate and diluted to 
ensure a concentration of 10^5 cells in each well. Fresh media was added to give a final volume of 2 mL 
of media/well. The plates were incubated at 37°C with 5% v/v CO2.  The 24 well wells were counted in 
triplicate on day 1, day 3, and days 5-10. 
2.3.6 Cell Appearance 
LC-540 cells were photographed at 400X magnification using a microscope camera. 
2.3.7 Steroid Analyses 
2.3.7.1 Preparation of hCG MEM 
hCG ( 10 mg, 100 IU) was dissolved in 1 mL of fresh MEM. The 1 mL of hCG medium was diluted 10-fold 
3 times to give a final concentration of 10 μg/mL. hCG media was added to fresh MEM (199.6 mL) to 
give a final concentration of 20 ng hCG /mL. 
2.3.7.2 ELISA Buffer Preparation 
NaH2PO4.2H2O (6.24 g), Na2HPO4 (8.66 g), NaCl (9.0 g) were dissolved in milli Q water (800 mL). BSA (1 g) 
and thiomersal (0.1) were added and the pH adjusted to 7.0 with HCl or NaOH as required. The buffer 
was made up to 1 L and stored at 4°C until required. 
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2.3.7.3 Cell seeding and incubation 
LC-540 cells (18 flasks) were seeded in MEM (20 mL) with approximately 3 x 106 cells and incubated 
overnight. Following incubation, the MEM was vacuum aspirated and replaced with either control MEM 
(i.e. no hCG, n=9) or hCG-containing MEM (n=9). Every 24 hours, three samples of spent  control and 
hCG MEM were collected. The media was centrifuged at 4000 xg/5 min and filtered through a 0.22μm 
syringe filter. The cells were detached using 2.5% trypsin and counted (see section 2.3.4).  
2.3.7.4 Steroid extraction   
The filtered, spent MEM (5 mL) was poured into a 50 mL separation funnel. Diethyl ether (15 mL) was 
added and the funnel was capped and shaken vigorously. The cap was removed and the layers were left 
to separate for approximately 2 min. The aqueous and organic layers were collected separately. The 
aqueous layer was returned to the separation funnel and the process was repeated 2 more times. In 
total the steroids were extracted using 3 x 15 mL of ether. The ether was dried with sodium sulphate 
(approximately 3 g) for 10 min. The ether was filtered into a fresh 250 mL RBF and evaporated under N2. 
Fresh ether (6 mL) was added to the RBF and swirled to dissolve the extracted. The ether was then 
carefully poured into a 7 mL glass vial.  Ether (1 mL) was added to the RBF and swirled before being 
added to the same 7 mL vial. The ether was evaporated under nitrogen and the extract was dissolved in 
ELISA buffer (500 μL). The samples were stored at 4°C until analysis. 
2.3.7.4 ELISA Analysis 
See Section 5.3.8 
2.3.7.5 Statistical Analysis 
The testosterone production was normalised against the cell count to produce the amount of 
testosterone per 106 cells. The standard deviation and standard error of the mean were calculated. A 




A flask of confluent LC-540 cells was removed from incubation. The monolayer was detached and 
pelleted (see 2.2.3.2). The pellet was suspended in MEM (500 μL) containing 17% v/v DMSO (100 μL). 
Aliquots (100 μL) were added to sterile 1 mL cryovials. Each cryovial was wrapped in cotton wool and 




2.4 Results  
2.4.1 Growth Characteristics 
The LC-540 cells exhibit a typical growth pattern consisting of an initial lag phase, a rapid log phase and 
finally a plateau phase (Fig. 2.1). The cells had a lag phase of approximately 4 days where the cells had a 
doubling time of 2.5 days. At day 5 the cells enter the log phase where the growth is at the maximum 
rate with a doubling time of 1 day. At day 7, the cells enter the plateau phase and the rate declined to a 
doubling time of 22 days. The growth curve indicates that the cells can be grown long term in culture. 
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2.4.2 Cell Description 
The LC-540 cells from a very thin, flat monolayer. The monolayer consists of wide spherical or oval 
shaped cells with a large extracellular matrices (ECMs) which overlap (Fig. 2.2). Like other Leydig cells, 
lipid droplets and what appears to be mitochondria can been seen throughout the cytoplasm. When 
detached from the flask surface the cells peel off in a single sheet of spherical cells before breaking up 

























Figure 2.2: LC-540 cells under 400X magnification. The tumour cell line appears to maintain some key features 
of primary Leydig cells such as lipid droplets. 
N 
ECM = Extracellular matrix 
LC = Leydig Cell 
N = Nucleus 
LD = Lipid droplet 
M = Mitochondria 
65 
  
2.4.3 LC-540 Steroid Production  
LC-540 cells have the capacity to produce testosterone with and without hCG stimulation in culture over 
72 h (Fig. 2.3). The levels of basal and hCG stimulated production is highest in the first 24 h. The 
testosterone produced by LC-540 cells over 24 h is 255 ± 47 pg/106 cells and 395 ± 26 pg/106 cells for the 
basal and hCG-treated respectively. The levels drop significantly at 48 h to 108 ± 29 pg/106 cells and 88 ± 
35 pg/106 cells for the basal and hCG stimulated respectively. The levels do not vary much at 72 h with 
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Figure 2.3: The basal and hCG stimulated production of testosterone by LC-540 cells over 72 h. The levels of 
testosterone are significantly higher in the first 24 h before dropping at both 48 and 72 h. 
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2.5 Discussion  
The key aims of the LC-540 models system were to evaluate the growth, appearance and steroidogenic 
potential of LC-540 cells in culture and access their suitability as a model for DBP toxicity. 
2.5.1 LC-540 growth and Appearance   
The results of the LC-540 growth curve (Fig. 2.1) clearly illustates that LC-540 cells can be maintained 
long term in culture. This demonstrates that the culture procedure is robust and provides the required 
conditions and growth factors for long term cell maintenance. The long term maintenance of cells 
ensures the cellular biology and biochemistry remains intact. The appearance of the cells (Fig. 2.2) 
demonstrates that the cells are viable in culture and the biology remains intact. There have been has 
been one published study on the growth rates of LC-540 cells.67 This study demonstrated that LC-540 
cells have longer than typical lag phases. In comparison to most cell lines, LC-540 cells have a nearly 2-
fold longer lag phase. This is perhaps due to the culture procedure which utilizes trypsin proteases to 
breakdown the extracellular matrix.  It has been suggested that may cell lines only enter the rapid log 
phase in culture after ECMs begin to overlap. Therefore, it is possible that LC-540 cells are highly 
dependent on this phenomenon and require longer in culture to reach their log phase. The long term 
maintenance of LC-540 cells is essential in the present study as it is the basis for most of toxicological 
experiments. If the cells had limited growth in culture, they would not be a viable model system as the 
subsequent experiments relied on the constant expression of genes that code for enzymes that produce 
and metabolise DBP and synthesize testosterone. If the cells had not rapidly divided in culture is highly 
likely that the cells would have regressed and their biochemistry diminished. There have been no 
published studies on the appearance of LC-540 cells in culture; however, Leydig cells isolated from 
human and animal testes have been well characterized. The appearance of LC-540 cells in the present 
study demonstrate that the specific biology and biochemistry of Leydig cells (e.g. steroid producing 
organelles) are largely intact and that overall the cells are highly functional. There are key limitations in 
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both the growth curve and cell appearance methods. Firstly, the growth curves rely on small aliquots of 
cells and extrapolating to give a total count for a total volume of cell suspension. This process can have 
high error, and even in triplicate, can still be inaccurate. LC-540 cells tend to clump, even with the use of 
trypsin protease, clumps still persist. This can reduce errors in the extrapolated counts. A more robust 
procedure to improve the growth curve experiment and determine the total number of cells would be 
to extract and quantify the total DNA of the cells in the suspension. This would prevent the need to 
extrapolate from a smaller volume. The cell appearance in the present study was limited as only simple 
microscopy was used (i.e. 400x magnification). This only allows the visualization of some organelles. The 
identification of these organelles is done solely on appearance rather than histochemical reactions 
which can be more definitive. A technique to improve the overall microscopy would be cyro-electron 
microscopy. This would provide much more rich cellular detail and give a more clear indication of the 
biology and biochemistry of LC-540 cells. 
A key aim of the present study was to characterize the LC-540 cells in culture and to assess their viability 
as a model system. It is clear based upon the results of the growth and appearance that LC-540 cells are 
indeed a viable in culture. The most important consideration is the steroidogenic potential of LC-540 
cells in culture. 
2.5.2 The Steroidogenic Potential of LC-540 Cells in Culture 
The present study clearly demonstrated the potential of LC-540 cells to produce testosterone in culture 
with and without stimulation by hCG. Therefore, LC-540 cells are a viable model system or evaluating 
the toxicity of DBP. The stimulus by hCG is indicative of intact LH receptor (LHR) on the surface of the 
cells and a functional adenylate cyclase pathway. This demonstrates that expression of LHR on the 
surface of the LC-540 cells is maintained in culture. Research into other Leydig cell lines have 
demonstrated that the expression of LHR is diminished or completely absent. In those cell lines there is 
likely clonal evolution that selects clones that have reduced LHR expression in favour of other factors to 
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increase growth. The levels of testosterone are approximately 10-fold lower than isolated primary 
Leydig cells,127 This is likely due to a reduction in expression of key genes in testosterone biosynthesis. 
Research into other Leydig cell lines have identified a significant reduction of CYP17 protein synthesis.131 
This is likely the case with LC-540 cells and explains the reduced testosterone production. There has 
been a study on the levels of testosterone produced by LC-540 cells with and without stimulation by 
hCG. In that study the levels of testosterone reached a maximum level of approximately 70 pg/106 cells 
at 72 h.127 This is in contrast to the present study which reaches a maximum level of testosterone at 24 
h. This could be due to the LC-540 cells in the present study having more steroidogenic potential 
compared with the LC-540 cells in the other study by Santucci et al.127 The increased steroidogenic 
potential could be due to the LC-540 cells in the present study not undergoing clonal evolution and 
maintaining more steroidogenic potential. This is likely as the cells used were a low passage number (i.e. 
lower time in culture). The reduction over the subsequent 48 and 72 h is likely an artefact of the 
experiment. The testosterone excreted by the cells after 24 h is almost certainly re-entering the cell and 
interfering with steroidogenesis. Testosterone has been shown to be an inhibitor of both 17β-HSD and 
3β-HSD. Therefore, if any testosterone re-enters the cell it could disrupt testosterone synthesis. The cell 
would likely respond by forming testosterone glucuronides the cell or by binding testosterone to steroid 
binding globulins. The study by Santucci et al127 also demonstrated that LC-540 cells were able to be 
stimulated over 72 h by hCG. This is in contrast to the present study which has no significant changes 
after 24 h. This could be due to an increase in LHR in the present study. The steroidogenic capacity is 
increased and it is highly likely that the expression of LHR is also increased compared to the cells in 
Santucci et al.127 Therefore, the hCG would undergo degradation much faster and so the levels of hCG at 
48 and 72 h would be too low to have an effect.  
There are some limitations in the present study. The testosterone levels are much lower than in primary 
Leydig cells. Therefore, to analyse the levels, the spent MEM needed to be concentrated from large 
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volumes. This extraction procedure is time consuming and would almost certainly have involved the loss 
of testosterone (up to 10%). This is typically overcome in other analyses (e.g. high performance liquid 
chromatography, HPLC) by the use of an internal standard. However, the use of an immunoassay 
prevents the addition of an internal standard. Therefore, there is no data on the recoveries following 
ether extraction. The levels of testosterone are normalised against cell count which can be erroneous 
(discussed above). Therefore, normalising the testosterone levels against quantities of DNA could be a 
more accurate and reliable method. The present study only measured the levels of free testosterone in 
spent MEM. More data is required on the levels of steroid hormone binding globulin levels as it is highly 
probable that a majority of the testosterone was bound to a globulin after 24 h. A glucuronidase digest 
could also be used to determine the levels of testosterone glucuronides.  
The key aim of the present study was to evaluate the suitability of LC-540 cells as a viable model; 
particularly evaluating the steroidogenic potential of the cells with and without stimulation by hCG. It is 
clear that LC-540 cells are a viable model for DBP toxicity as they have an intact steroidogenic pathway 
capable of producing testosterone. The observable stimulation by hCG demonstrates the functional cell 
signalling pathway is intact and the expression of cell surface receptors is maintained. The growth, 
appearance and biochemistry of LC-540 cells in culture further suggest their viability as a model system 

















DBP is still widely used in many consumer, food and civil industry products, owing to its effectiveness in 
increasing both the plasticity and fluidity of plastics and its relatively low production costs.1 Despite 
restrictive legislation in some industrialized countries (e.g. limits on acceptable food levels, banned in 
children’s toys)1, bio-monitoring data suggest ubiquitous and high daily DBP exposure to the general 
population.135 Various studies136,137 have linked the indirect exposure via DBP-containing food and 
consumer goods as the potential source of high daily exposure in adults.130,131 Continued exposure to 
DBP (and other phthalates) could be having a sustained impact on the reproductive health of humans 
and other higher organisms receiving environmental exposure. 
DBP production is still in the millions of tonnes annually and the many DBP-containing products are 
often discarded into the environment. The estimated environmental release in the USA was 177 tonnes 
into the water, air and soil in 1999.138 Therefore, there is a risk of DBP leeching into the environment. 
This is of particular concern when phthalates are being leeched into the human water supply (e.g. into 
streams and water treatment facilities). The metabolism of DBP by microorganisms (Fig. 3.1) has been 
shown to produce MBP (i.e. a toxic metabolite of DBP) which could leech into the water supply, 
exposing humans to higher levels of MBP compared from DBP exposure alone. Chemical degradation 
also occurs through the de-esterification of DBP to phthalic acid by water. 
Exposure to DBP (and other environmental pollutants) occurs through two distinct exposure routes: 
direct and indirect. Direct exposure is uncommon and involves the direct intake of these chemicals; 
usually during their manufacturing process.139 Indirect exposure occurs when DBP leeches into the 







The exposure occurs through ingestion, inhalation (e.g. indoor air and dust) dermal (e.g. from 
cosmetics) or by leaching from PVC into water and soil.137 As 100% of DBP is excreted by humans within 
24 h,135 there is little accumulation of DBP over time. Therefore, the daily exposure levels are a direct 
indication of the likely risk of posed by DBP exposure. The exposure levels are often compared to two 
established levels; namely the tolerable daily intake (TDI, the daily level of exposure that does not pose 
a risk long term risk and the MRL, the daily exposure level at which there is not likely to be any non-
carcinogenic health effects. 
3.1.2 Indirect Exposure  
DBP is used extensively as a plasticizer in a variety of plastics such as PVC and nitrocellulose polymers 
(see Section 1.2). These plastics are cheap and easy to manufacture and so have become ubiquitous in 
modern times. Therefore, the risks of DBP (and other phthalates) leeching into the environment is a 
serious issue around the world. During the manufacture of plastics, DBP is incorporated into PVC and 
nitrocellulose. However, DBP is not covalently bonded to the polymer molecules bur rather held in place 
Figure 3.1: The Biodegradation of DBP in the environment 
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by weak Van der Waals forces.136 These intermolecular bonds can be easily broken at low temperatures 
(between 25-30°C). Therefore, it is highly likely that the DBP in some plastics will leeching over time. 
3.1.2.1 Ingestion of DBP 
3.1.2.1.1 Adult Dietary Exposure 
Ingestion of DBP through food that comes into contact with DBP-containing products (packaging, etc.) 
has been demonstrated to be a major exposure route.140 DBP-containing packaging can allow migration 
of DBP into the foods, particularly those that have a high fat content.140 While modern packaging 
plastics typically do not contain DBP (likely due to consumer pressure), contact and contamination of 
DBP into food still occurs during processing; e.g. equipment used in food production is often made from 
or contains DBP, which can leach into food during processing.140 The EU Scientific Committee for Food 
has set a guideline of 6 mg DBP/kg as the limit for acceptable DBP levels into food for human 
consumption.141 A study conducted in the United Kingdom compared a high fat and a regular healthy 
diet for DBP intake.142 Analysis of urinary metabolites suggested a considerable difference in high and 
low fat diets with levels of 31 µg DBP/kg bw/day and 13 µg DBP/kg bw/day respectively. Studies 
conducted in Switzerland140 and Denmark143 analysed daily DBP intake for an average and healthy diet. 
The calculated daily intake was considerably higher in the average diet; nearly a ten-fold increase 
compared to the reported DBP levels in the healthy diet studies. The large increase in whole diets is in 
accordance with European data on DBP levels present in individual foods.140 Sugars and cereals, a large 
majority of the western diet, have high concentrations of 603 µg DBP/kg and 565 µg DBP/kg 
respectively. This represents significantly higher dietary exposure compared to levels in animal 
products, which are reported as approximately 100 µg DBP/kg.142 These data suggest that if western 
diet trends continue (e.g. increasing daily sugar consumption) daily DBP exposure may also increase.  
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3.1.2.1.2 Infant Dietary exposure 
Infants and toddlers appear to have the highest daily exposure to DBP of any age group.140 Several 
studies have investigated the levels of DBP in the diet of children aged 0-3 years. New-borns have a 
primary diet of breast milk and/or infant formulae, while toddlers usually begin to eat baby foods 
between 6-12 months. The levels of DBP in breast milk is very low and of little concern. A study 
investigating DBP levels in the breast milk of German woman found a mean concentration of 0.82 µg 
DBP/kg, which gives a daily intake of approximately 0.6 µg DBP/kg bw/day assuming the mean 
consumption per day is 0.75 kg.144 These results are in accordance with similar studies conducted in 
Canada145 and Sweden146 which reported DBP concentrations of 0.5 µg DBP/kg and 1.5 µg DBP/kg in 
breast milk respectively. Data from China147 reported ten-fold higher concentrations of DBP in the milk 
of 40 women. The Chinese study reported mean concentrations of 54 µg DBP/kg which would indicate 
daily intakes for new-borns at 60 µg/kg bw/day,147 under the MRL of 100 µg/kg bw/day.  
Studies have been conducted to determine DBP concentrations in baby foods and infant formulae. An 
analysis of 11 different brands of baby food and infant formulae found baby food samples contained 
between 10-20 µg DBP/kg while the infant formula was slightly higher at 10-100 µg/kg.148 This is 
consistent with an earlier study which reported 20-85 µg DBP/kg and 10-55 µg/kg for baby food and 
infant formula respectively.149 With intakes of 60 µg DBP/kg bw/day via the ingestion of food diet 
contributes significantly to the observed high daily intake of infants. This along with the potential of 
other routes of exposure could pose a risk of DBP toxicity for infants. 
3.1.2.1.3 Exposure in Drinking Water 
DBP can migrate into drinking water from the DBP-containing plastics which holds water and other 
drinks that use phthalate esters as plasticizers.144 The use and long term storage of drinking water in 
polyethylene (PE) and polyethylene terephthalate (PET) bottles has been shown have levels of DBP150-
152. Analysis of water in both PE and PET bottles after 10 weeks storage found levels of DBP increased 
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from initially undetectable levels of DBP to 0.046 μg DBP/L for both bottle types.151 Another study found 
that the levels of DBP in water stored in DBP-containing plastic bottles for 30 days was much higher at 
11.33 μg DBP/L.150 The study did not measure the DBP levels before the 30 day storage.  Incidentally, 
the same study analysed DBP concentrations in soft drinks contained in the same type of plastic bottles 
and found a range of 9.00-26.75 μg DBP/L.  Water stored over 5 months has been shown to increase the 
DBP concentration up to 20% from 2.0 μg DBP/L to 2.4 μg DBP/L.152 Interestingly, the many studies have 
large ranges of DBP concentrations in drinking water. This could be due to large variations in the 
phthalate levels used to manufacture of plastics can be up to 50% w/w of the polymer.153 
DBP has also been shown to contaminate drinking water when DBP-containing plastics are discarded 
into fresh water supplies or by PVC piping. Analysis of tap water in China154 and Japan155 found 1.4 and 
2.4 μg DBP/L respectively. Tap water in California was found to be considerably lower, ranging from 
1.44-8.34 μg DBP/L.156 This is in agreement with tap water levels in Germany with ranges of 0.12 to 8.80 
μg DBP/L.157 
3.1.2.2 Inhalation 
Since humans spend up to 80% of their time indoors, the Inhalation of compounds in indoor air and dust 
can represent a major exposure route.158 Therefore, it is essential to evaluate the levels of contaminants 
including DBP in the household air and dust. As DBP is semi-volatile, it can be released the air or by 
coming into contact with dust and leaching into the particles.159 DBP has been detected in the 
household dust in numerous studies.160-165 Therefore, when humans inhale this air and dust, they are 
likely to be indirectly exposed to DBP. 
A study of 120 homes in North Eastern USA found a range of DBP levels in household air. All the homes 
studied had some levels of DBP ranging from 0.052 to 1.1 μg DBP/m3 air.161 The levels in dust in the 
same study were found to be 20.1 mg DBP/kg dust. A study of 30 homes in Germany (selected by the 
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presence of PVC flooring, pipes, etc.) found a median level of 87.5 mg DBP/kg dust.165 Another German 
study of 59 apartments and 74 kindergartens found median air levels of DBP at 1.1 and 1. 2 μg DBP/m3 
air respectively.163 Analysis of the dust in the same apartments found 47 mg DBP/kg dust. The levels of 
DBP in 390 Swedish bedrooms found higher levels of DBP with a median of 150 mg DBP/kg dust.162 The 
levels of DBP are relatively low in these studies compared to studies in Italy160 and Bulgaria164 which had 
DBP levels of 799 and 7,860 mg DBP/kg dust respectively. 
The data demonstrates the wide range of DBP levels in air and dust worldwide. The variability in DBP 
levels can likely be attributed to the consumer behaviour relating to the use of DBP-containing plastics 
in the home. Overall the consensus of the data is that household exposure via inhalation is a major 
source of DBP exposure. 
 
 
3.1.2.3 Dermal absorption 
The application of some DBP-containing products on the skin can facilitate the indirect exposure of DBP 
via dermal absorption. Cosmetics, personal care and cleaning products often contain DBP and are the 
most likely household products to contact the skin. There is a lack of data surrounding the levels of 
dermal exposure to DBP. The quantification of dermal absorption is challenging as there is a wide array 
of DBP-containing products that could come in contact with the skin.  
A comprehensive study of 253 cosmetics and personal care products commercially available in Canada 
found detectable levels of phthalates in a range of products.166  DBP levels were as high as 6.6 μg DBP/g 
of shampoos, body sprays, cleansing wipes and body lotions. However, nail polish levels were 
significantly higher at 24304 μg DBP/g polish.166  Analysis of personal care and cosmetics available in 
Spain found levels of DBP in the some types of products as high as 141 μg DBP/g of product, with 
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particularly high levels of DBP in hand creams.167 Analysis of nail polish available in South Korea found 
3901 μg DBP/mL polish.168 
The data demonstrate the ubiquity of DBP in personal care and cosmetic products. However, the risk of 
dermal DBP exposure is still an area of conjecture. Dermal absorption of DBP is slow in most areas of 
human skin.169 Some areas (e.g. facial skin) pose a greater risk of absorption as these areas have much 
thinner layers of skin. Therefore, DBP-containing facial creams and shampoos (i.e. shampoo comes into 
to contact with the face during washing) can pose a greater risk of DBP absorption. There is significant 
higher levels of DBP in nail polishes compared to other cosmetics. Therefore, those who use large 
volumes of it daily (e.g. manicurists) have a much higher risk of DBP exposure. This has been 
demonstrated by the high levels of DBP metabolites found in the urine of manicurists.170 The levels of 
DBP in nail polish can lead to exposure levels well above the TDI. Long term application of DBP-
containing nail polishes could potentially pose a significant risk; particularly to pregnant woman where a 
low doses can have significant effects on the developing embryo.  
It is clear that indirect exposure is the most common route of DBP exposure for the average human. 
There ubiquity of DBP ensures daily human exposure is almost unavoidable regardless of geographical 
location and consumer choices. The effects of DBP at the normal population daily exposure levels are 
not fully known.  
3.1.3 DBP Daily exposure levels 
3.1.3.1 Typical Human Exposure  
Legislative variations and consumer behaviour is likely a major contributor to the worldwide variation in 
daily human DBP exposure. Normal population daily exposure levels are estimated by analysis of urine 
concentrations of DBP metabolites1,171. USA data over a six year period indicates the normal population 
daily exposure is estimated to be in the range of 0.08-113 µg DBP/kg bw/day.149 A study conducted in 
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Germany over a period of 9 years established daily exposures in the range of 0.22-116 µg DBP/kg 
bw/day. 171The maximum exposure levels in these studies are well over the TDI (10 µg DBP/kg 
bw/day)172 and slightly above the MRL (100 µg DBP/kg bw/day).1 Therefore, the acute daily DBP 
exposure in the USA and EU could pose a risk to the reproductive health of the general population. As 
China, North America and Europe account for the majority of the world's DBP production and use, the 
exposure levels elsewhere in the world is are presumably lower in comparison. Data from two studies 
conducted in Asia have shown a considerable lower daily exposure to DBP for adults.173,174 The daily 
exposure in China and Japan ranged from at 8.70-12.5 µg DBP/kg bw/day and 1.20-2.20 µg DBP/kg 
bw/day respectively. The low levels in China are counter-intuitive (China is considered to be the world 
leader in DBP production) but suggests differing consumer behaviour of the Chinese people; i.e. less 
fatty diet and less use of cosmetics, etc.  
The normal population daily DBP exposure levels are perhaps the most important to quantify as they 
provide insights into the real risk DBP poses to humans on a daily basis. However, they are much lower 
compared to occupational exposure levels which are upwards of 10-fold higher.170 
3.1.3.2 Occupational exposure levels 
Occupation exposure is uncommon and specific to DBP production or manufacturing of DBP-containing 
products. The exposure is unique as it represents the only source of direct exposure today.  However, as 
the exposure is specific, the data published to date is scarce. One study analysed several industries 
involved in either DBP production or used products containing high levels of DBP.170 The study found 
large increases in the levels of DBP metabolites in the urine of workers in those industries compared to 
the general population. The levels of DBP exposure in workers involved in commercial DBP synthesis, 
rubber gasket and rubber hose manufacturing are 25, 26 and 10-fold higher respectively than the 
normal population.170 Interestingly, the same study found manicurists have a 2.7-fold increase in daily 
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DBP exposure compared to the average person. This has been linked to the high levels of DBP found in 
nail polish. The maximum levels detected in all the four industries all exceeded 100 µg DBP/kg bw/day. 
Therefore, those involved in these industries have a significant higher risk of DBP toxicity (e.g. poor 
semen quality, reduced testosterone levels).175,176  
Most people are exposed to the ubiquitous environmental pollutant DBP daily in the developed world. 
Therefore, it is essential that the associated risk of daily and occupational exposure is fully understood. 
Presently, there is a consensus that the daily exposures levels pose no risk to humans.1 However, as the 
mechanism of toxicity is not fully understood, there is potential for effects to humans at the daily 
exposure levels. It is clear the occupational exposure of DBP is at levels that could affect the 
reproductive health of workers involved in the manufacture of DBP-containing products. The long term 
exposure to DBP at low levels may have effects that have yet to be identified. Therefore, it remains 
important to evaluate the risk of DBP at both normal population and occupational exposure levels. 
 
3.2 Research Objectives 
The aim the research described in this chapter is to determine the DBP levels for use in the LC-540 cell 
exposures and evaluate whether the cells can tolerate these exposure levels. This will be done via the 
following research goals: 
 Selecting the most appropriate exposure concentrations to reflect the general population 
exposure, occupational exposure, and New Zealand Malayan Veterans’ exposure and calculate 
the concentrations to best represent the average human. 




 Determine the cell growth response to the levels of DBP to evaluate their suitability in for gene 






3.3.1 Calculation of Exposure levels  
The daily exposure level was calculated using a range of exposure data from normal human exposure 
levels.149 The range of daily exposure is between 0.08-113 µg/kg bw/day. Therefore, the TDI was chosen 
as the daily levels as this in within the range and is a widely accepted value.  The assumptions used to 
calculate the exposure levels are listed in Table 3.1. 
 
 
3.3.2 LC-540 Exposure 
The exposure standards and MEM were prepared using only glassware. No plastics were used to 
prevent contamination of DBP. Two exposure mediums (1X and 2X) were prepared as appropriate. The 
1X exposure was used for exposures in 75 cm2 culture flasks. The 2X exposures were used during the 






Human Body Weight177   70 kg 
Blood level178 75 mL/kg bw 
General population exposure1 TDI 
Occupational exposure170 10 x  General population exposure 
New Zealand Malayan Veterans179 50 x  General population exposure 





3.3.2.1 Preparation of Exposure Standards 
 The 5 mg/mL DBP exposure standard was prepared using a 10 µL Hamilton syringe to add DBP (4.76 µL, 
5 µg) to a 4 mL glass vial. The DBP was dissolved in of 1 mL HPLC grade ethanol and inverted 20x. The 







3.3.2.2 Preparation of Exposure medium 







The 2X exposure media was prepared similarly, however, 200 µL of each standard was added to the 
culture medium to give final concentrations of 0, 0.2, 2, 10 µL/mL of culture medium. 
DBP Standard Dilution Standard (volume used) Ethanol  
1  mg/mL 5 mg/mL (200 µL) 800 µL 
0.1  mg/mL 1 mg/mL (100 µL) 900 µL 
Control 0 1000 µL 
Exposure Medium concentration DBP standard (volume used) Volume of fresh MEM 
5 µg/mL 5 mg/mL (100 µL) 100 mL 
1 µg/mL 1 mg/mL (100 µL) 100 mL 
0.1 µg/mL 0.1 mg/mL (100 µL) 100 mL 
Control control (100 µL) 100 mL 
Table 3.2: Preparation of the exposure standards 
 




3.3.2.3 1X LC-540 exposure 
The 1X exposure of LC-540 cells always occurred when cells were approximately 50-60% confluent in 75 
cm2 culture flasks. This was done to ensure the cells were not in the lag or plateau phase. The spent 
MEM was vacuum aspirated and replaced with 20 mL of 1X exposure MEM. The cells were left to 
incubate until required. 
3.3.3 Growth Curves  
The cell seeding procedure was carried out as outlined in section 2.5.4 (i.e. seeding 105 cells/well). The 
2X exposure medium was used to allow for the normalization of the cells at 105 cells/well. Each well was 






3.4.1 Exposure Level Calculations 
The general population exposure DBP concentrations used in the present study was calculated from the 
following formula: 
 
   






The general population blood level was calculated to 0.1 µg DBP/mL blood. The occupational exposure 
levels are 10 and 50-fold higher than the daily respectively; therefore, they were calculated from the 
general population exposure concentration to give 1 µg DBP/mL blood and 5 µg DBP/mL blood 
respectively. The absorption was assumed to be 100% and so the final concentrations of the exposure 
medium were 0.1 µg DBP/mL MEM, 1 µg DBP/mL MEM and 5 µg DBP/mL MEM for the general 
population, occupational and NZMVs respectively (Table 3.4). 
 
Dose Exposure level  
Daily exposure 0.1 µg/mL culture medium 
Occupational exposure 1 µg/mL culture medium 
NZ Malayan Veterans’ 
exposure 
5 µg/mL culture medium 
 
 
 ED = Daily blood level (µg/mL) 
 TDI = tolerable daily intake (µg/kg bw/day) 
 BW = body weight (70 kg) 
 BV = blood volume (5250 mL) 




3.4.2 Determining the LC-540 growth rates following DBP exposure 
 The growth of the LC-540 cells following exposure to varying concentrations of DBP is shown in Figure 
3.2. None of exposure levels have any major cytotoxic effects. The 0.1 µg DBP/mL, 1 µg DBP/mL 
exposure levels and control groups all appear to have the same growth patterns (e.g. comparable 
sigmoid curves).  These groups all reach a maximum number of approximately 2.4 x 106 cells after 10 
days. The 5 µg DBP/mL exposure level has a significant effect on the growth of the cells. The maximum 
cell number is diminished by 30% to 1.8 x 106. The lag phase is also slightly extended to 5 days 
compared to 4 for the control, 0.1 µg DBP/mL, 1 µg DBP/mL exposure levels 
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Figure 3.2: The growth of LC-540 cells following varying DBP concentrations. The growth rates are 
approximately the same for the controls, 0.1 and 1 µg DBP/mL. The 5 µg DBP/mL dose appears to have 





There are two key questions when investigating the effects of DBP on the LC-540 cells. Firstly, what are 
the appropriate exposure levels? Secondly, what unintended cytotoxic effects will these exposure levels 
have on the cells? 
3.5.1 The Calculated Exposure Levels 
The exposure levels in the present study were selected to best represent the daily human exposure 
levels that are or have been observed and published. The exposure levels were calculated on some 
common assumptions. The average person was assumed to be 70 kg177 and have 75 mL of blood/kg.177 
The absorption of DBP into the blood was assumed to be 100%. 
The normal population exposure level in the present study represents the best estimate based on 
recent exposure data. The aim of this calculation was to demonstrate the effects of DBP on Leydig cells 
at the TDI. There have been few studies published that evaluate the effects of DBP at level on animals. 
The exposure studies in animals typically involve doses that far exceed the normal human daily 
exposure. The animal studies have determined the NOAEL to be 100 mg DBP/kg bw/day1. Therefore, 
those studies have not detected any observable effects lower than the 100 mg DBP/kg bw/day. 
However, these studies often do not focus on the effects to the cells of the animals (e.g. genomic 
changes). Genomic changes following normal population daily DBP exposure have been shown in R2C 
cells.67 Therefore, levels in the present study were chosen to further evaluate the effects of low level 
DBP exposure in Leydig cells. 
The occupational exposure levels have been reported to be 10-fold higher than that of daily intakes. 170 
Therefore it is logical that in the present study we multiply the daily dose the cells are exposed to (i.e. 
0.1 µg/mL) to give the appropriate dose. This value represents the highest possible dose (outside of 
extreme isolated incidents) that humans can be exposed to in the present day. This level will give 
insights into the more extreme effects DBP can have on humans in modern times. 
87 
  
The final exposure level represents the dose that the New Zealand Malayan Veterans were exposed to 
during the Malayan Emergency.179 The exposure of soldiers to DBP has been linked to reproductive 
malformations of their male offspring in multiple generations. Therefore, at this dose it is highly likely 
that real toxic effects could be observed. However, this dose appears to have significant cytotoxic 
effects in LC-540 cells. 
There are limitations with the exposure level calculations. There was the necessity for a range of 
assumptions based upon widely accepted values. The occupational exposure is based upon limited data. 
The lack of other major occupational exposure studies could reduce the accuracy of the exposure level.  
3.5.2 The Cytotoxicity of DBP in LC-540 Cells  
The present study demonstrates that DBP exposure at the normal population and occupational daily 
levels do not have any major cytotoxic effects in LC-540 cells. The cell number and growth rate was 
unchanged following exposure at 0.1 and 1 µg DBP/mL concentrations (Fig. 3.1).  Therefore, the DBP 
exposure does not have any major effects on the biochemistry of the cell. This is essential for the overall 
viability of the LC-540 model system. If the DBP exposure levels had a much larger cytotoxic effect on 
the cells, the validity of gene expression results would be questionable.   
Model systems can produce artefacts of the experimental conditions that would not otherwise occur in 
humans. This is particularly problematic when investigating the toxicity of compounds that have been 
reported to be cytotoxic.67 This was observed at the 5 µg DBP/mL exposure level. The cells had poor 
growth throughout the experiment at this exposure level. There were large numbers of dead cells 
present initially. This is similar to a study investigating the effects of DBP at this concentration in R2C 
cells. The author postulated that high doses of DBP can interfere with membrane fluidity.67 The cells in 
the present study did recover over time and the viability increased. However, the growth potential was 
severely impacted with the log phase ending with 30% less maximum growth. This is similar to the 
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reported effects of another study which demonstrated significant reductions is cell growth after 72 h in 
culture at high levels of DBP.180 The cytotoxicity of high levels of DBP can not only induce apoptosis, but 
severely impact the biochemistry of the cell. A cell that exhibits diminished growth in culture following 
exposure to high levels of DBP can have broad scale alterations to gene expression that are unrelated to 
the mechanism of toxicity of DBP. This could lead to many false positives in a gene expression assay and 
therefore, severely affect the validity of the results.  The possibility of clonal evolution is particularly 
high; i.e. as there is a large initial die off, the stronger, DBP resistant cells are selected.  These clones 
might prevent DBP from exhibiting much of toxic effects on the cell and diminish its effects and 
potentially give a false negative. It is clear that the LC-540 model system does not tolerate 5 µg DBP/mL 
of DBP. Therefore, it can be concluded that DBP mechanisms of toxicity experiments cannot be carried 
out at 5 µg DBP/mL. 
There are limitations to the growth curve. As discussed in Section 2.5.1, the growth curves can have high 
error due to the nature of cell counting. Therefore, the quantification of DNA could provide a more 
accurate picture of the changes in growth following DBP exposure.  
The aim of the research in this chapter was to calculate the best exposure levels for the DBP 
mechanisms of toxicity experiments and evaluate the cytotoxicity to LC-540 at these exposure levels. 
The results demonstrate that 0.1 DBP/mL and 1 DBP/mL represent the best estimates for normal 
population and occupational daily exposure levels. These levels do not have major cytotoxic effects of 



















4.1.1 Xenobiotic Metabolism 
The ability of organisms to break down and excrete unknown and potentially toxic compounds is 
essential for survival. Nearly all organisms possess the biochemical framework known as xenobiotic 
(from the Greek ‘xeno’ meaning strange and ‘bioticos’ meaning related to living) metabolism which 
allows for the detoxification and excretion of most compounds.181 The process has three key steps; 
namely, oxidation, conjugation and excretion.182 The xenobiotic metabolism can have a role in disease. 
This occurs via with the modification of compounds (with low toxicity) into metabolites that are harmful 
to an organism.182 A good example is the conversion of the procarcinogen (i.e. a compound converted 
into a carcinogen in vivo) benzo[a]pyrene into the more toxic, mutagenic benzo[a]pyren-7,8-
dihydrodiol-9,10-epoxide (Fig. 4.1).183 However, xenobiotic metabolism is essential in the detoxification 
of drugs (e.g. warfarin) and other compounds that could otherwise harmful or even fatal if left 
unmodified184 (i.e. most drugs are lipophilic and cannot be excreted in the body’s water-based excretion 
system).185 When investigating the pharmacology of compounds, it is essential to understand not only 




















4.1.2 Phase I metabolism 
The first phase of xenobiotic metabolism is an oxidation step whereby compounds are modified to 
increase their polarity. However, other reactions such as hydrolysis, reduction, cyclization or 
decyclization are used.186 The primary objective of Phase I metabolism is to attach and activate 
nucleophilic functional groups to facilitate excretion or provide sites for conjugation (i.e. for Phase II 
metabolism).186 The primary metabolising enzymes are the family of CYP monooxygenases. CYP 
enzymes are primarily localised the endoplasmic reticulum of hepatocytes; however, they are also 
present in most cell types (except the brain). The enzymes are all heme-thiolate proteins that 
incorporate Fe ions in catalysis.187 The general reaction of CYP enzymes (Fig. 4.2) incorporates NADPH in 
a catalytic cycle (Fig. 4.3).187 
 
Figure 4.1: The bioconversion of benzo[a]pyrene to the carcinogen benzo[a]pyrene-7,8-dihydrodiol-9,10-
epoxide. The resulting epoxide can intercalate into DNA causing irreparable damage to DNA resulting in 
















4.1.2.1 Alkyl Hydroxylation 
A common reaction of CYPs is the addition of an hydroxyl to an alkyl chain via carbon hydroxylation (Fig. 
4.4).188 The oxidation process can occur multiple times on the same site (e.g. carbon) to further convert 
alcohols into aldehydes and carboxylic acids. The process can also be repeated following loss of 
formaldehyde which reduces the length of alkyl chain to facilitate chain breakdown and reduce the 
lipophilicity of compounds (this is an essential part of fatty acid metabolism).189  Carbon hydroxylation 
may be the final step before excretion188 as this can produce a molecule of sufficient water 
Figure 4.2: The general scheme of cytochrome P450 oxidation. The reaction uses NADPH as an 
oxidation/reduction cofactor. The result of the reaction is typically oxidation of xenobiotics.  
Figure 4.3: The CYP catalytic cycle. The cycle begins with a reaction between the heme Fe of the CYP and the 
xenobiotic. The Fe
3+
 in the active site undergoes reduction to Fe
2+ 
with concomitant oxidation of the 




solubility.190,191  However, most often excretion requires the addition of a conjugate to ensure the 






4.1.2.3 Oxidation of Unsaturated Carbons 
The metabolism of unsaturated carbon bonds (e.g. alkenes, aromatic rings, etc.) is perhaps the most 
‘dangerous’ of the Phase I metabolism processes. The formation of epoxide intermediates, particularly 
common among poly aromatic hydrocarbons (PAHs), potentially produces toxic compounds that can 
interact with DNA.183  Epoxides are unstable and can spontaneously degrade or be hydrolysed by epoxy 
hydrolase to form phenols (Fig. 4.5).192  As epoxides are unstable they have not been isolated in 
metabolism studies, however they’re presence is inferred by the formation of the phenoxy compounds 
and their conjugates.  The mechanism of epoxide and phenol formation is not fully understood; 
however, there are several possibilities such as carbocation (e.g. Sn1 reaction), radical or carbon-Fe 
intermediates.192 
There are many other Phase I processes to increase the polarity of xenobiotics, however at the end of 
Phase I the compounds are often unable to excreted without the conjugation step of Phase II 
metabolism. 
 
Figure 4.4: The enzyme-catalysed mechanism of an alkyl hydroxylation. The process goes through a radical 











4.1.3 Phase II metabolism 
The primary function of Phase II metabolism is to conjugate the xenobiotics to highly water soluble 
moieties that both increases water solubility and obliterates toxicity. This ensures their excretion and 
inactivates any pharmacological properties of the compound (i.e. Phase I metabolism leaves the 
molecules largely unmodified which often maintains the xenobiotic’s biochemical activity).193 The 
enzymatic conjugation reactions form much more water soluble products that and typically excreted via 
specially designed transfer proteins.193 The conjugates are typically glucuronide, sulfide, acetyl, 
glutathione and amino acid (e.g. glycine) moieties. The enzymes that facilitate conjugation are 
transferases that utilize a variety of cofactors. The conjugation mechanisms vary between organisms, 
with humans primarily having glucuronide or glycine conjugation (40-70% of all drugs are 
glucuronidated).194  
 
Figure 4.5: A potential scheme of unsaturated carbon epoxidation and hydroxyl formation. The epoxide forms 




Glucuronidation, the most important of the Phase II metabolism processes utilizes a superfamily of 
Uridine diphosphate (UDP) glucuronyltransferases (UGTs).195 The UGT superfamily has 117 mammalian 
isoforms (humans have four). All UGTs are membrane bound proteins that catalyse the covalent O-
linkage between uridine-5  -diphospho-α-D-glucuronic acid (UDPGA) and nucleophilic carbons, alcohols, 
amines (primary, secondary, tertiary), thiols and carboxylic acids (Fig. 4.6).195,196 Interestingly, the 
reaction involves the inversion of the stereochemistry  of glucuronic acid from α (when bound to a UGT) 





The formation of β-D-glucuronides is only the first step of detoxification, the molecules must be 
transported across the endoplasmic reticulum membrane into the cytosol whereby they are excreted 
into urine and bile.197 
4.1.3.2 Sulphonation 
Glucuronidation is the most common form of conjugation; however some organisms have little UGT 
activity. Therfore, these organism utilize other conjugation reactions (e.g. sulfotransferases, SULTs). 
SULTs are a superfamily of enzymes that catalyse the formation of 3’-phosphoadenosine 5’-
phosphosulphate (PAPS) conjugates with molecules containing nucleophllic O, S or N groups (Fig. 4.7).198 
Figure 4.6: A general scheme of glucuronidation. The UDPGA transfers glucose to a xenobiotic. The reaction is 
characterized by an inversion of the stereochemistry.  
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PAPs is a universal donor in all sulfonation reactions (its importance is highlighted by the fact that can 





There are two classes of SULTs; namely, cytosolic and membrane bound.200 The cytosolic forms are 
primarily involved in sulfonation of cytosolic (i.e. more polar) xenobiotics and endobiotics (i.e. cellular 
molecules). Membrane-bound forms are located on the Golgi apparatus and conjugate sulphates to 
lipids, proteins and carbohydrates.201 Sulfonation has high biochemical functionality outside of 
xenobiotic metabolism and is essential is biotransforming low-molecular weight biomolecules such as 
steroids. SULTs are found in a plethora of tissues including brain, liver, endometrium and intestine, 
breast, and owing to its steroid conjugation functionality, in the testis.200 Like all Phase II metabolism 
products sulphonates are excreted in the urine and bile. 
4.1.3.3 Glutathione Conjugation 
Glutathione-s-transferases (GSTs) represent another major Phase II metabolism process that is essential 
in protecting cells from oxidative stress and potentially toxic electrophiles (e.g. reactive oxygen species, 
ROS); many of which are formed by the activity of monooxygenases (e.g. CYPs ).
202 GSTs are utilized to 
Figure 4.7: A general scheme of sulfonation. The PAPS transfers a sulphate functional group.  
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breakdown ROS species (e.g. epoxides and peroxides). GSTs are often found conjugated to PAHs 
following Phase I metabolism.203 The GST family of enzymes form O-linked thioether conjugations 





There are two distinct forms of GSTs; namely, soluble GSTs and membrane bound GSTs (membrane-
associated proteins in eicosanoid and glutathione metabolism, MAPEGs).203,204 The soluble isoforms are 
dimeric enzymes responsible for detoxification of xenobiotics and endobiotics.203 Interestingly, while 
these enzymes are primarily found in the cytosol, they have been detected in the nucleus, mitochondria 
and peroxisomes.204 Conversely, MAPEGs are thought to be trimeric enzymes responsible for 
arachidonic acid metabolism.205 The two forms of GST are widely distributed in mammals. GSTs have 
been detected in the brain, liver, kidney lung, intestine, muscle and testis among others.204 
 
4.1.4 Transport Proteins and Excretion 
The final step in xenobiotic metabolism is the excretion of the detoxified compound; typically in bile or 
urine.193 In most cases, cell transport proteins are essential in removing xenobiotics from within cells.206 
The efflux proteins, adenosine triphosphate (ATP)-binding cassette (ABC) transporters represent a 
Figure 4.8: The conjugation of glutathione to a xenobiotic via GST.  
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diverse range of proteins that facilitate the removal of compounds from cells (using ATP as an energy 
source).207 Naturally, these proteins have a diverse range of substrates, including both conjugated and 
unconjugated xenobiotics.208 There are 49 known genes in the ABC family209 which code for seven 
isoforms ABCA to ABCG; each distinguished by domain and amino acid homology.210 
The ABC proteins contain two ATP-binding folds (nucleotide binding folds, NBF), two sets of 
transmembrane domains (TMDs, each containing six membrane-spanning α-helices).211 The NBF folds 
are cytoplasmic and bind ATP to push the xenobiotic through the membrane211. As the NBF domains are 
only found in the cytoplasm, the ABC transporters act only as efflux proteins. The TMDs alternate 
between in-ward and out-ward conformations while NBFs alternate between open and closed states.211  
The mechanism of efflux is not fully understood however the contemporary thinking is that multidrug 
binding proteins (MDBPs) initially transport the detoxified xenobiotics to the NBFs.212 Subsequent ATP 
binding and hydrolysis in a region between the NBFs closes and brings the two folds 10-15 Å closer 
together. This flips the TMDs outwards, pushing the xenobiotic through the membrane and outside the 
cell.212 
4.1.5 DBP metabolism 
The metabolism of DBP into MBP (and other metabolites) is an important consideration when 
investigating mechanisms of toxicity.  The MBP has been demonstrated to be more toxic than DBP at 
the same concentration in vivo.213 This suggests that MBP metabolism is the initial step of DBP toxicity. 
There has been considerable work done on DBP metabolism in rats.214-218 The proposed metabolism in 
rats (Fig. 4.9) consists of the major metabolite, MBP and its glucuronide conjugate (approximately 90-
95%) with other minor products being phthalic acid (up to 2%) and CYP oxidised metabolites (up to 
10%).203,204 N-butanol is often not measured in DBP metabolism studies; however, it is almost certainly 
the produced along with MBP in the first metabolism step (i.e. the hydrolysis of DBP to form MBP). Both 
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glucuronidation and CYP oxidation are thought to occur in the endoplasmic reticulum of hepatocytes; 
however, as these enzymes are found in many tissues, it is likely these metabolism processes occur in 
other locations (e.g. skin, Leydig cells). The metabolites of DBP (including glucuronides) have been found 
in the blood and urine.  
Interestingly, analysis of metabolites in rat serum has found MBP to be in predominantly the free form 
(80-90%).  However, in humans the inverse is true with only 25-30% being free MBP while the 




Figure 4.9: The proposed metabolic pathway of DBP in rats. The primary metabolite is MBP. Other hydroxyl 





The DBP metabolic pathway in humans is difficult to measure as it is ethically challenging to dose 
humans. However, one such study has measured the DBP metabolites in human urine following a single 
oral dose (Fig. 4.10).135 The primary metabolite detected was MBP (90%). The oxidation products of 
MBP were also detected; 3-hydroxy-monobut-1-ol phthalate (3-OH-MBP), 4-hydroxy-monobut-1-ol 
phthalate (4-OH-MBP), 2-hydroxy-monobut-1-ol phthalate (2-OH-MBP) and 3-carboxy-monopropyl 
phthalate (MCPP) accounted for 6%, 0.7%, 0.1% and 0.3% respectively.135  The ratios of glucuronide 
products were not analysed as all samples were treated with glucuronidase before analysis.135 However, 






Figure 4.10: The proposed metabolic pathway of DBP in humans. The primary metabolite is MBP. Other 





4.1.6 Potential Estrogenicy of DBP 
DBP has the potential to act as a xenoestrogen in vivo (previously discussed in section 1.5.1.2). The 
metabolism of DBP in vivo may in fact contribute the estrogenicity via oxidation at key sites (Fig. 4.11). 
This potential metabolite, mono(4-butanol)-4-hydroxyphthlate (M4B-4HP) has a possible structural 





Figure 4.11: the potential metabolism to an estrogenic DBP metabolite.     
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4.2 Research Aims  
The aim of this research described in this chapter is to evaluate potential estrogenicity of a theoretical 
DBP metabolite, analyse the metabolism of DBP in cultured LC-540 cells and determine if the estrogenic 
metabolites are produced and evaluate the estrogenicity of DBP exposure at physiologically relevant 
exposure levels. This will be done via the following research goals: 
 Conduct in silico modelling studies to evaluate the structural analogy of M4B-4HP and E2 in the 
ER. 
 Investigate the Phase II metabolism of DBP using a glucuronidase enzymatic digest.  
 Evaluate the major DBP metabolite/s produced in LC-540 cells following exposure 24 h using 
HPLC. 





4.3.1 in silico modelling studies 
The modelling was done using ChemBio 3D software. M4B-4HP was drawn using ChemBio 3D. The ER 
coordinates were download from the PDB into ChemBio 3D and M4B-4HP was overlayed with E2 in 
bound in the active site using the fast overlay function. The key binding residues were identified and 
distances between them and the overlayed M4B-4HP were measured. 
4.3.2 Preparation of Bufffers, standards and enzymes 
4.3.2.1 Preparation of exposure standards 
The Exposure standards were prepared as outlined in section 3.3.2.1 
4.3.2.2 Preparation of Internal Standards 
Ethinyl estradiol (EE2, 0.25 mg) and 4-nitrophenol-D-β-glucuronide (4NPG, 0.5 mg) were dissolved in 
HPLC grade ethanol (10 mL). 
4.3.3.3 Preparation of Glucuronidase Buffer 
The buffer was prepared by dissolving sodium acetate trihydrate (13.6 g) in milli Q water (80 mL). The 
solution was adjusted to pH 5.0 using glacial acetic acid and topped up to 100 mL using miili Q water. 
This gave a final concentration of 100 mM. 
4.3.3.4 Preparation of Glucuronidase  
Glucuronidase powder (20 mg, 38400 U) was dissolved in milli Q water (5 mL) to produce a 7610 U/mL 
solution. 
4.3.3 DBP metabolism, Glucuronidase Digest and Extraction  
4.3.3.1 Preparation of Exposure Medium 
The 1 µg/mL, 1X exposure medium was prepared as outlined in section 3.3.2.2 
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4.3.3.2 DBP Exposure 
LC-540 cells (10 flasks) were grown to semi-confluence. The flasks were divided into two groups: 
exposure group (n=5) and control (n=5). The exposure group was exposed to 1 µg/mL DBP (see section 
3.3.2.3).  Both cell groups were left to incubate.   
4.3.3.3 Culture Medium Collection and Glucuronidation 
The spent MEM was collected at 1 h, 8 h, 12 h and 24 h. The spent MEM was centrifuged to remove any 
cells. The MEM was divided evenly into two 10 mL aliquots. EE2 (0.25 µg/mL) EE2 (0.5 µg/mL) 4NPG (0.5 
µg/mL) was added to each aliquot. Glucuronidase (735 µL, 10000 U) was added to one 10 mL aliquot 
giving a concentration of 1 U/ µL MEM.  The MEM was added 1:1 in glucuronidase buffer. The 
glucuronidase medium (pH 5.0) was left to incubate at 37°C for 2 h.  
4.3.3.4 Culture Medium Extraction 
The 10 mL aliquots were extracted in diethyl ether (3 x 30 mL). The ether was collected in a 250 mL RBF. 
The ether was dried using sodium sulphate (approximately 9 g). The ether was dried under N2 for 15 
min. The extract was dissolved in ether (5 mL) and the RBF was swirled gently for 10 s. The ether was 
poured into a 7 mL glass vial. A further 2 mL of ether was added to the RBF and swirled before being 
poured into the vial. The ether was again dried under N2 and the extract was dissolved in HPLC grade 
ethanol (500 µL). The samples were filtered through a 0.22 µm filter into 2mL vials and stored at 4°C 
until analysis. 
4.3.4 HPLC 
All samples were analysed using a C18 reverse phase column and a step gradient. Each run included a 
solvent only and ethanol only blank. The UV absorbance was measured using a photo diode array 
detector (DAD) at 210, 235, 280 and 330 nm. Each sample had 20 µL injected per analysis. 
4.3.4.1 HPLC preparation  
A Dionex brand HPLC system was used for all analyses. The HPLC needle was washed using 10% (v/v 
aq) MeOH and primed 5 times with 10% (v/v aq) MeOH. The HPLC system was purged (5 mins, 3 
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mL/min) with a solvent mixture comprising 10% Acetonitrile containing 0.1% v/v formic acid (FA), 
90% MilliQ water containing 0.01% v/v FA. 
4.3.4.2 Mobile Phase 
Two elution buffers were used: Buffer A; 99.9% Milli Q water containing 0.01% v/v FA, Buffer B; 
99.9% Acetonitrile containing 0.1% v/v FA 
A single gradient was used for all analyses: 
90%A 10%B-50%A 50%B (0-20 min), 50%A 50%B (20-25 min), 50%A 50%B-10%A 90%B (25-45 min), 
1%A 90%B (45-55 min), 10%A 90%B-90%A 10%B (55-60 min), 90%A 10%B (60-65 min). 
4.3.4.3 Identification of Metabolites 
DBP, MBP, EE2 and 4-ntrophenol (4NP) analytical standards were run before injection of sample 
batches. The peaks that co-chromatographed with the standards peaks were identified as either MBP or 
DBP. The fractions of any unknown peaks were collected as identified by mass spectrometry. 
4.3.4.4 Calibration Graphs 
A stock solution of DBP, MBP and EE2 (300 mg/L ethanol) was prepared in a single volumetric flask. The 
stock solution was shaken vigorously and inverted 20 times to fully dissolve the compounds. The stock 
solution was diluted to produce standards of 0.5, 1, 2.5, 5, 10, 15, and 20 mg/L. The standards were 
filtered through a 0.22 µm filter into a HPLC vial. Each standard had three injection replicates. The peak 
areas were correlated with concentration. Linear regression analysis was performed to give the 
coefficient of determination (R2). This was used to determine the accuracy of the standard curve 
(i.e. the standard graph was only used if R2 > 0.99). 
 4.3.3 MCF-7 Proliferation Assay 








4.4.1 in silico Modelling Studies 
The in silico model shows that M4B-4HP has significant structural analogy with E2 in the ER active site 
(Fig. 4.12). M4B-4HP orientates in the active site in such a way that the key binding groups of the ER 
(Glu 353, Arg 394, and His 524) are in a position that would likely allow for binding of M4B-4HP. The key 
active site residues of the ER active site: Glu 353, Arg 394, and His 524 have of 2.9, 3.3 and 2.8 Å 





Figure 4.12: The in silico model of M4B-4HP overlayed in the active site with E2. There is structural analogy 
with E2 in the ER binding site. 
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4.4.2 Method Validation  
4.4.2.1 Mobile phase  
The two analytical standards available; DBP and MBP (the most likely metabolite) were effectively 
separated in the multi-step gradient by approximately 20 min (Fig. 4.13). The addition of FA into the 
mobile phase lowers the pH of the mobile phase (approximately pH 2.5). This protonates the molecules 
in each sample, ensuring consistent, sharp peaks. 
 
 
4.4.2.2 Glucuronidase and Extraction Internal Controls 
The success of the glucuronidase reaction is identified by presence of 4NP in the chromatogram. The 
cleavage of the glucuronide from 4NPDG yields 4NP. The 4NP standard ran at 14.0 min. This peak was 
found in all the glucuronidated extracts. The extraction internal standard was EE2. The EE2 standard ran 
at 22.65 min. This peak was found in all chromatograms. 






4.4.2.3 Standard Curves 
The standard curves of DBP, MBP and EE2 all have good linear regression with R2 values >0.999 (Fig. 
4.15). The linear nature of the calibration graph allows for the reliable calculation of DBP and MBP 
concentrations 
4.4.3 Xenobiotic Metabolism in LC-540 Cells 
4.3.3.1 LC-540 Glucuronidation 
LC-540 cells have high glucuronyl transferase activity and form a range of glucuronide excretion 
products (Fig. 4.16). The majority of excretion products exist as glucuronides. 
Figure 4.14: The chromatogram of a glucuronidated control extract. The 4NP and EE2 peaks are present 

























R2 = 1.0000 





















Figure 4.15: The calibration graphs of DBP, MBP and EE2. The R2 values are all >0.999. 
R2 = 0.9999 
R2 = 0.9998 


















































Figure 4.16: The comparison of extracts from untreated (A) and glucuronidase-treated (B) spent LC-540 MEM 
after 1 h incubation. The untreated media has few peaks. The glucuronidase-treated media demonstrates that 









4.3.3.2 DBP metabolism 
The metabolism of DBP in Leydig cells occurs primarily over 8 h. The exposed Leydig cells convert most 
of the DBP into MBP. The majority of MBP is subsequntly glucuronidated. Over the next 16 hours the 
levels of MBP decrease. At 24 h, some DBP remains unmeatbolised. There were no other detectable 




Figure 4.17: Levels of DBP and MBP in spent LC-540 MEM over 24 h. DBP is mostly metabolised over 8 h. The 






4.4.4 MCF-7 Proliferation Assay 
The MCF-7 cells are able to grow in culture over 8 days and have a typical sigmoidal growth curve (Fig. 
4.18). DBP stimulates significant increases in cell division at the general population and occupational 
daily exposure levels. Interestingly, the general population exposure level (i.e. the lower dose) had a 
greater effect than the occupational exposure level. The general population exposure level had an 
approximately 70% increase in final cell number compared to controls. The occupational exposure level 
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Figure 4.18: The MCF-7 proliferation in response to daily and occupational exposure levels of DBP. The cell 




There remains little conjecture in the literature concerning the anti-androgenic like effects of DBP. 
However, there is no consensus on the potential of DBP being estrogenic. The present study produces 
conflicting evidence:  estrogenic metabolite/s were not detected in any extract of the culture medium 
of LC-540-exposed; however, a MCF-7 proliferation assays demonstrated a slight an estrogenic effect. 
There are many questions to consider; namely, how reliable is the in silico modelling? Was the analytical 
methodology sensitive enough to detect M4B-4HP? Are there other factors that influenced the MCF-7 
proliferation assay?. 
4.5.1 in silico Modelling 
4.5.1.1 The Use of M4B-4HP 
The in silico model focused on structural homology between M4B-4HP and E2 in the active site of the 
ER. M4B-4HP was chosen as it is a logical product of Phase I metabolism of DBP in vivo; i.e. the oxidation 
of the phenyl and alkyl groups of MBP, the major metabolite of DBP. These oxidations occur commonly 
in the metabolism of a range of xenobiotics. Therefore, it is entirely logical that this product would be 
produced in some capacity. The key question is: how much of this metabolite is produced and is it 
excreted by the cell? 
4.5.1.2  in silico Software 
The modelling software used was ChemBio 3D, a relatively cheap and user friendly modelling program 
that has been used previously to investigate the molecular mimicry of molecules in the active site of 
receptors.220 The software runs PDB coordinates and allows molecules to be overlayed on other 
molecules bound in the active site (i.e. agonists). This allows a molecule of interest to be viewed in an 
active site in a probable conformation in vivo. This information can allow for many postulations 
regarding the potential for that molecule to an agonist. Unlike more sophisticated software (e.g. 
Schrödinger),221 the interactions with the protein itself are not considered. The sole focus is on the best 
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fit model of the two overlayed compounds. The lack of protein interactions impacts the overall 
reliability of the model.  
There are key structural features of E2 that xenoestrogens mimic that allow them to bind to the 
hydrophobic binding pocket of the ER: the phenolic hydroxyl, a hydrophobic backbone and an aliphatic 
carbon. M4B-4HP does possess these key features and therefore has estrogenic potential (Fig. 4.12). It is 
these features that allow the molecule to have a structural analogy with E2 in the in silico model. 
Therefore, it can be assumed that M4B-4HP would have very similar interactions with the hydrophobic 
binding pocket of E2. 
The model system has some key limitations but does give some insights into the potential estrogenicity 
of M4B-4HP. As is the case with all models systems, the model must be backed up with experimental 
evidence. In terms of estrogenicity, this is the MCF-7 proliferation assay. However, its estrogenicity is 
irrelevant if it is not produced in vivo. The use of Schrödinger along with ChemBio 3D would improve the 
validity of the model. 
4.5.2 DBP Metabolism in LC-540 Cells 
The investigation of metabolism of DBP in the present study had three main goals: to evaluate the 
major metabolites of DBP in LC-540 cells, to ascertain if LC-540 cells have the potential for Phase II 
metabolism (i.e. glucuronidation and sulfonation) and the detection of M4B-4HP. 
4.5.2.1 Phase II metabolism in LC-540 Cells 
A major Phase II metabolism processes in mammals including rats is the glucuronidation of 
xenobiotics.222 There are other minor conjugates such as amino acid conjugates and sulfonates. These 
modifications are designed to facilitate the excretion of the xenobiotics from the cell; usually involving 
ABC transporters. The functional metabolism of xenobiotics has implications in the viability of the LC-
540 models system. If the cells cannot modify and excrete DBP, the unmodified DBP is free to exert a 
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greater toxic effect; i.e. unmetabolised DBP would affect the Leydig cells more than would normally 
occur in vivo. Leydig cells in vivo metabolise and excrete xenobiotics quickly (usually between 6-36 h). 
The LC-540 cells are tumour cells and therefore, susceptible to reductions in expression of multiple 
metabolism genes (e.g. CYPs and transferases).221 However, it is evident that LC-540 cells retain the 
expression of glucuronyl transferases as the concentrations of a variety of excretion products are much 
higher in the glucuronidase treated extracts (Fig. 4.16).  The present study clearly demonstrates that 
there is minimal MBP in non-treated extracts compared with the extracts treated with glucuronidase 
(>90%).  This suggests that the majority of MBP is glucuronidated. This is in contrast with DBP 
metabolism studies involving the oral administration to rats.216 The urinary levels of MBP in rats had 
over 90% free MBP. The present study only investigated the metabolism of DBP in Leydig cells; 
however, Foster et al.216 studied the urinary metabolites. The urinary metabolites are comprised of 
mutiple metabolism processes in other organs (e.g. via the liver, gut etc.). It is highly likely that these 
other systems favour excretion of free MBP of MBP-glucuronides. It is clear that MBP is harmful to 
Leydig cells; therefore, LC-540 cells may glucuronidate the MBP in response to a toxic effect exerted on 
the cells.  As MBP is not harmful to the liver and most other organs, there is little need to detoxify to the 
extent needed by Leydig cells. 
The present study utilised a β-glucuronidase enzymatic digest of the spent culture medium. The β-
glucuronidase used in the experiments was isolated from helix pomatia and has minor sulfatase activity. 
To ensure all glucuronides present in the spent culture medium were deconjugated, the concentration 
was set at the standard of 1 unit/µL culture medium. The standard buffer was 0.1 M sodium acetate pH 
5.0. The enzymatic reaction requires a pH range of 4.0-5.0 and so the culture medium was added 1:1 v/v 
which yields a pH of 5.0. The reaction limited to 2 h and clenched by adjusting the pH to approximately 
7.4 using NaOH. This prevented the hydrolysis of DBP and MBP (and potentially other metabolites) 
which can occur in aqueous solution under acidic conditions. There is some apparent hydrolysis in the 1 
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h Glucuronidase-treated extract. The same media was divided evenly into the un-treated and 
glucuronidase treated groups; however, the levels of DBP are much lower in the glucuronidase treated 
groups, a 5-fold decrease. It is clear that the conditions for deconjugation of glucuronides are 
unfavourable for esters under acidic conditions.  
4.5.2.2 DBP Metabolism 
The present study used HPLC to investigate the metabolites of DBP following exposure of LC-540 cells. 
DBP is metabolism begins rapidly and after 1 h, approximately 40% of the DBP is converted to MBP-
glucuronides. Over the next 8-24 h, most of the DBP is metabolised, with only trace amounts remaining. 
Interestingly, the levels of MBP decrease rapidly during the same time period. The reduction in MBP 
concentration is likely due to the MBP-glucuronides re-entering the cell and being further metabolised. 
Therefore, this observation is an artefact of the experiment as the MBP in vivo would be readily 
transported away from the Leydig cells and  excreted in the urine.216 There was no detection of M4B-
4HP in any of the samples using HPLC. However, M4B-4HP would almost certainly be excreted as a 
glucuronide. There is the possibility that the acidic conditions of the glucuronidase digest could have 
degraded M4B-4HP. This molecule is likely to be produced in small amounts and therefore, following 
acid degradation, M4B-4HP could possibly be below the limit of detection.  
Other studies investigating DBP metabolism found trace amounts of oxidised MBP metabolites (e.g. 4-
hydroxy-MBP). 204 The present study did not find any of these compounds in trace amounts. This may be 
due to the possible hydrolysis of these metabolites during the Glucuronidase treatment.   
There were some limitations of the present study. The metabolism experiment was not done in 
replicate. This was due to time constraints. The metabolism of DBP in LC-540 cells occurs primarily 
between 1-8 h. There was no analysis of between this time period. As the majority of DBP metabolism 
occurs during this period, subsequent metabolism studies should evaluate the levels of DBP and MBP 
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over this timeframe. HPLC may not be sensitive enough to detect the minor metabolites of DBP. A more 
sensitive analytical methodology such as liquid chromatography-mass spectrometry (LC-MS) could 
increase the limit of detection. It might be possible identify M4B-4HP and other metabolites using LC-
MS.   
While no M4B-4HP was detected, the estrogenic effects of it, or some other molecule is implied in the 
MCF-7 proliferation assay. 
 
4.5.3 MCF-7 Proliferation Assay 
MCF-7 cells are a breast cancer cell line with expression of ERs α and β.223 Upon binding to E2 (or other 
xenoestrogens) the ERs dimerize and enter the nucleus to upregulate the expression of cell cycle genes 
to increase cell proliferation. MCF-7 cells have been used to determine the estrogenicity of compounds  
in culture.224 The MCF-7 proliferation assay has a distinct advantage over the YES assay; the ability to 
metabolise the exposure compound. This is vital when the compound is a pro-estrogenic (i.e. is 
converted to an estrogenic molecule via metabolism), as is likely the case with DBP. Indeed, many 
studies have overlooked the estrogenic potential of DBP as assays like the YES assay do not produce 
conclusive results (i.e. the YES assay demonstrates little DBP estreogenicity).61  However, when you 
evaluate the possible metabolic routes in vivo, it is clear that the biosynthesis of an estrogenic 
metabolite is possible.  No study to date has published a MCF-7 proliferation assay involving DBP. The 
present study does not find such any metabolite in extracted culture medium of DBP-exposed LC-540 
cells. However, the effects of an estrogenic molecule can be seen in the MCF-7 proliferation assay.  
The results of the MCF-7 proliferation assay demonstrate that DBP has a significant effect on the growth 
rate of MCF-7 cells in culture. The cells were exposed to the normal population (0.1 µg DBP/mL) and 
occupational (1 µg DBP/mL) daily exposure levels. The greater effect was observed in the normal 
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population exposure level which had the greatest effect on MCF-7 proliferation compared to the 
controls and occupational exposure level. The occupational exposure level did increase the growth of 
the MCF-7 cells but to a much smaller extent than the normal population exposure level. This could be 
due to the MCF-7 cells sensitivity to DBP; i.e. there is an initial ‘die off’. This is followed by an estrogenic 
stimulation of DBP to increase proliferation after the cells recover. There is also the possibility of clonal 
evolution; i.e. after the initial die off, the remaining cells are more resistant to DBP compared to the 
daily exposure level. This effect is observable in effects of some drugs which have a maximum effect 
dose. Any dose above this level has significantly lower effect.225  
An interesting observation in the MCF-7 proliferation assay is the effect of DBP continues throughout 
the 8 day course of the experiment despite DBP being mostly metabolised at 24 h. This suggests the 
possibility of epigenetic modification. As described in section 2.1.5.2, MCF-7 cells are prone to 
epigenetic modifications in culture. There is a strong possibility DBP is effecting the epigenome as 
exposure to DBP is known to cause a wide range of epigenetic modifications in vivo.81 
The MCF-7 proliferation assay has limitations. Firstly, cells in vitro are highly variable and have irregular 
growth patterns. Therefore, without more evidence, (e.g. detection of estrogenic metabolites in spent 
MEM) the estrogenic effect of DBP is not conclusive. The errors associated with cell counting (see 
Section 2.5.1). Other methods of cell quantification should be used in future work to validate the cell 
counts. 
The present study has demonstrated that LC-540 cells have a robust Phase I and Phase II metabolism 
that converts DBP to MBP. The presence of M4B-4HP was not detected; however, its effects are implied 
in an MCF-7 proliferation assay. More work is needed to fully evaluate the metabolism of DBP in LC-540 
cells; including a more sensitive analytical methodology to determine metabolites below the limit of 

















The biosynthesis of steroid hormones is essential in many higher organisms to regulate metabolism, 
healthy sexual development, cellular stress, immune functionality and maintain reproductive health.65 
Steroids are endocrine signalling lipid hormones with a conserved sterol structure of three fused six-
membered rings and one five-membered ring.226,227  Steroids can be found in most higher organisms 
such as animals,228 plants229 and fungi.230 The many hundreds of steroids discovered go date are all 
biosynthesized from squalene. Squalene is synthesized via the cyclization of lanosterol and cycloartenol 
in animals and plants respectively.230,231 The production of steroids in animals is regulated by the 
steroidogenesis biosynthetic pathway. Active steroid hormones are synthesized in the gonads, adrenal 
glands and placenta;65 beginning at early gestation in humans with production of progesterone and 
continuing throughout life.232 
Four main classes of steroids in humans are known; namely, the androgens (e.g. testosterone), 
estrogens (e.g. E2), the progestogens (e.g. progesterone) and the glucocorticoids (e.g. cortisol).233 These 
steroids are produced in different glands and bound to the steroid binding globulins (e.g. testosterone 
binding globulin) which transport the steroids through plasma.234 Steroids circulate the body, acting on 
specific tissues. Steroids may have profound impacts on the tissues they interact with. Therefore, their 
biosynthesis is highly regulated.66 The unregulated production of steroids has been linked to the 
feminization of men via disruption of the androgen:estrogen ratio.235 The regulation of steroid 
biosynthesis is controlled in part by signalling hormones excreted from the pituitary gland and gene 
regulatory effects.66 However, exposure to some environmental EDCs can disrupt this regulation and 
perturb some steroid specific tissues. 
To understand how the effects of environmental EDCs on steroidogenesis and steroid dependant 
tissues, it is essential to understand the regulation, synthesis and function of steroids hormones. 
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5.1.1 Cholesterol biosynthesis 
In all organisms, all steroid hormones are synthesized from the lipid cholesterol230. This essential lipid is 
of course found in the membranes of all cells and is a precursor to many other bioactive molecules (e.g. 
vitamin D).236 The synthesis of cholesterol (Fig. 5.1) occurs primarily in the liver via a multi-step pathway 
beginning with the cyclization of squalene.230 Firstly, squalene is oxidized by a monooxygenase to form 
Squalene-2,3-epoxide. The straight chain terpeneoid squalene folds into a sterol-like conformation and  
cyclizes via the enzyme 2,3-oxidosqualene:lanosterol cyclase. This yields the typical sterol fused ring 
structure (i.e. three six membered rings and a single five membered ring) of lanesterol.230 Several more 
enzymatic modifications occur before cholesterol in synthesized. The final step (inside the liver) is the 
acetylation step to yield a cholesterol ester.237,238 Lipoproteins carry cholesterol and cholesterol esters in 
plasma, delivering them to all tissues15 including the adrenal glands and gonads to undergo 
steroidogenesis. However, cholesterol cannot freely enter the inner mitochondrial membrane to 
undergo the first step of steroidogenesis. A series of signalling cascades must first occur first to ensure 
transport of cholesterol to the site of steroidogenesis. 
5.1.2 Gonadotropin Regulation of Steroidogenesis 
The regulation of steroidogenesis in the testis is highly dependent upon the actions of gonadotropin 
hormones secreted by the pituitary gland. The periodic secretion of LH induces the steroidogenic 
function upon binding to the LHR on the cell surface of steroidogenic cells.66 The binding of to the LHR 
initiates a cascade of cAMP-mediated events.239 The products of steroidogenesis also regulate the 
expression of hormone secretion (e.g. testosterone down regulates LH production).240 Overall there is 
tightly regulated complex feedback machinery ensuring the healthy production of steroids. 
5.1.2.1 Hormonal Stimulation 
The hypothalamus initiates the first step of steroidogenesis by secreting the gonadotropin-releasing 
hormone (GnRH), a decapeptide which binds to receptors on the surface of the pituitary gland.241 The 
binding of GnRH induces intracellular events that synthesize and release several gonadotropins; namely, 
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LH and follicle-stimulating hormone (FSH), the latter of which primarily aids spermatogenesis.241 The 
released LH binds to the LHR, a specific high-affinity transmembrane GPCR.239,242 Like many GPCRs, LHR 
is a heterotrimer consisting of an α, β, and γ subunits.243,244 The α subunit binds guanine triphosphate 
(GTP) or guanine diphosphate (GDP). Binding of LH to the LHR causes rapid exchange of GTP for GDP 
which, in turn facilitates the dissociation of α-subunit. The α subunit binds to adenylate cyclase, 
inducing rapid cAMP synthesis. However, the low GTPase activity eventually hydrolyses the GTP on the 
α-subunit, leading to dissociation from adenylate cyclase and reformation of the GPCR trimer. The 
increased cellular cAMP levels activate several kinases.244 These kinases phosphorylate several 
promotors to stimulate and initiate steroidogenesis.16 
There are two distinct cellular responses to increased cAMP levels; namely acute and chronic effects. 











Figure 5.1: The biosynthesis of cholesterol. The terpene squalene is first oxidised before cyclising into a 
sterol conformation. Lanosterol undergoes many other biotransformations to produce cholesterol esters 
which are transported around the body. 
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5.1.2.2 StAR  
StAR is an essential protein in the regulation of steroidogenesis. The activity of StAR directly induces a 6-
fold increase in steroidogenic activity.248 StAR is a 37 kDA protein belonging to the StAR-related lipid 
transfer (START) domain protein family.249,250 START proteins have a conserved α/β structured lipid 
binding domain (i.e. the START domain) comprises of ~210 residues. This domain represents the binding 
pocket specific for cholesterol.251 StAR has been a difficult protein to study as the purification procedure 
is difficult and costly.249,252 This in some way has contributed to the mechanism of StAR action being far 
from fully solved. It is known that StAR is up-regulated by the cAMP-dependant kinase action which 
phosphorylates promoters, increasing its transcription of steroidogenic enzymes.253 The proposed 
mechanism of action goes via pH-dependant binding and release of cholesterol. At neutral pH to slightly 
alkaline pH (i.e. in the cytosol), StAR binds to cholesterol and acts upon the outer mitochondrial 
membrane, facilitating its transport into the inner mitochondrial membrane.254-256 The pH is more acidic 
in the inner mitochondrial membrane (pH 5). This leads to protonation of the C-terminal α-helix, 
essentially opening the gate and releasing cholesterol.  
5.1.2.3 Chronic stimulation of Steroidogenic Enzymes 
The actions of LH and cAMP are essential for the chronic stimulation of steroidogenic enzymes.239 It is 
clear that the actions of cAMP dependant kinases257 phosphorylate steroidogenic promoters such as 
steroidogenic factor 1 (SF1).258 The role of SF1 and other promoters has been demonstrated by the 
increased de novo synthesis of several steroidogenic enzymes; P450SCC and CYP17.
180,259 In the absence 
of cAMP, CYP17 protein synthesis has been shown to cease in cultured Leydig cells after 48 h.260 
Interestingly, in the same study, P450SCC was able to maintain some de novo synthesis.
260  However, a 
reduction in CYP17 severely limits the production of androgen or estrogen hormones as CYP17 catalyses 
a key reaction in steroidogenesis (see section 5.1.3.2). The stimulation of cAMP appears to be non-
essential for the expression of 3β-HSD in cultured Leydig cells.261 This enzyme has been shown to be 
expressed at normal levels following the removal of cAMP stimulus in cultured Leydig cells. These 
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cultured cells were able to produce progesterone (a product of 3β-HSD), but had little to no androgenic 
capacity.261 The role of cAMP in the stimulation of androgen synthesis is almost certainly regulatory 
mechanism to prevent the unregulated biosynthesis of androgen hormones.  
5.1.2.4 Downregulation of Steroidogenesis 
Gonadal steroids have been show to act as a feedback regulators of the episodic release of GnHR from 
the hypothalamus. E2 is known to be an important regulator in GnHR262,263 with surges of secretion 
observed following administration of E2 in pre-ovulatory ewes.264 E2 plays a dual role in GnHR surges; 
firstly, during the first four hours, E2 increases synthesis and insertion of GnHR to its receptor265,266. 
Secondly, E2 stimulates a sustained GnHR surge 12-15 afters after administration.267 The role of E2 in 
up-regulating GnHR stimulation and activation is linked to the estrous cycle in women. During this cycle, 
large quantities of E2 are needed for the gametes to become estrous (i.e. fertile). Therefore, up-
regulation of GnHR secretion stimulates increased production of E2 in the ovum. 
Progesterone has been shown to decrease the frequency of GnHR pulses in vivo.268 It has been 
suggested that progesterone acts to reduce the number of GnHRs on the pituitary gland.241 This has 
been shown in cultured ovine pituitary cells which had decreases in GnHR protein and mRNA.269 The 
role of progesterone is essential during the luteal phase of the estrous cycle to ensure the gametes are 
developed and fertile. As E2 stimulates ovulation, it would be essential to reduce the levels of E2 
significantly during this phase. 
In men, there is a complex system of regulation involving the GnHR down-regulation from both 
testosterone and E2.270 This has been demonstrated in humans via the suppression of E2 and 
testosterone synthesis (via chemical castration in healthy men).  The reduction in the sex hormones 
increased LH and FSH levels 3-fold.271 The mechanism of down-regulation of LH expression in thought to 
be via the reduction of GnHR pulses accompanied with decreases in the sensitivity of the pituitary gland 
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to respond to GnHR.271 A down-regulation is expected in males as the overproduction of androgen 
hormones results in hypogonadism in males and possibly causes precocious puberty. The down-
regulation by E2 may be a response to prevent feminization by preventing the production of E2 via the 
shutdown of steroidogenesis.  
The regulation of steroidogenesis is complex and involves a feedback mechanism involving a variety of 
endocrine glands. The process of steroidogenesis inside the cell is complex with many branching chains 
in the pathway. 
 
5.1.3 Steroidogenesis 
The steroidogenesis biosynthetic pathway (Fig. 5.2) produces a variety of tissue specific products with 









The first catalytic reaction of steroidogenesis is the conversion of cholesterol to pregnenolone (Fig. 5.3) 
via the enzyme P450scc.
233 The ~140 kDa protein is found in the inner mitochondrial matrix. The reaction 
occurs via two sequential oxidations at C22 followed by C20. This is followed by cleavage between C20 
Figure 5.2: The steroidogenesis biosynthetic pathway. The synthesis of steroids uses a variety of enzymes in a tissue 
dependant manner. Sex hormones, androgens and estrogens are synthesised in the testis and ovum respectively. 
The glucocorticoids are synthesized in the adrenal cortex. 
129 
  
and C21 resulting in pregnenolone and isocaprotic aldehyde.272,273 All three steps in the catalytic 
reaction occur in the same active site and require a molecule of O2 and NADPH
274,275. The reaction takes 




There is a single gene that codes for the approximately 60 kDa protein; namely cyp11a1.276  Cyp11a is 
expressed in all steroidogenic tissues; e.g. the gonads, adrenal cortex and placenta.233 Interestingly, 
pregnenolone is synthesized in the brain suggesting expression of cyp11a1 in the brain.277 Pregnenolene 
is a neurosteroid that has been demonstrated to act as an allosteric inhibitor of several neuroreceptors 
(e.g. Gamma-aminobutyric acid, GABA) which protects the brain from the toxic effects of external 
agonists of these receptors.278,279 However, in the steroidogenic tissues it is predominantly metabolized 
to one of two other steroids; namely progesterone and 17α-hydroxyprogesterone by the enzymes 3β-
HSD and CYP17 respectively. 
Figure 5.3: The reaction catalysed by CYP11A. The carbon chain of cholesterol is oxidised twice before being 




CYP17 has dual functionality in the steroidogenic pathway, with two different substrates (Fig. 5.4).233 
Both reactions oxidise their respective substrates at C17 followed by further oxidation at the same 
position, resulting in cleavage of the C17-C20 bond. This yields the C19 steroids, androstenedione and 
dehydroepiandronstenedione (DEHA).280 Each reaction is a two-step process whereby the C17 of 
progesterone or pregnenolone is hydroxylated to form the intermediate 17α-hydroxyprogesterone or 
17α-hydroxypregnenolone.280 The C17-C20 bond is cleaved via the oxidative formation of the ketone 
producing the C19 steroid with concomitant loss of formaldehyde.281 As with all CYP enzymatic 
reactions, CYP17 utilizes an O2 and NADPH molecule. A single gene codes for CYP17 and the 
approximately 57 kDa protein is found in the endoplasmic reticulum; where, the necessary co-factors 
for catalysis are present.282 
Androstenedione has no major biological function (except as a metabolic intermediate to testosterone 
and other sex hormones). DEHA like androstenedione is also commonly a metabolic intermediate; 
however, it also has a wide range of biological applications and is the most abundant steroid found in 
human plasma.283 DEHA, like pregnenolone is a neurosteroid having similar allosteric inhibitory 
functions on the GABA receptor (among others).283 
As androstenedione and DEHA are intermediates to the sex hormones, CYP17 is expressed in the 
gonads. Interestingly, DHEA has been shown to up-regulate glucocorticoid synthesis as such is 
expressed in the adrenal glands despite not being an intermediate in glucocorticoid metabolism. 
The multi-substrate functionality of CYP17 is not uncommon of the steroidogenic enzymes. In fact, 3β-
HSD catalyses four different substrates into several products; including the biological essential 







The ketone at C3 is essential for the biochemical functionality of many steroids (e.g. testosterone, 
progesterone and cortisol). 3β-HSD catalyses the conversion of the C3 alcohol to a keto group is. The 
enzymatic reaction is a two-step process to convert the C3 alcohol to a ketone and transfer the alkene 
from the C5 to the C4 position via an isomerase (Fig. 5.5).284 Unlike the steroidogenic CYPs, 3β-HSD 
utilizes the cofactor NAD+ which is reduced to NADH during catalysis.284 3β-HSD is coded for by multiple 
genes that synthesize a protein of approximately 44 kDa.285,286 There are multiple isoforms of 3β-HSD 
(all found in the SEM). All the isoforms perform the same catalytic reactions; however, they are tissue 
specific (e.g. the human isoform I is found in the placenta, breast and skin, isoform II is located in the 
adrenal gland, ovary and testis).287,288  
There are four products catalysed by 3β-HSD: progesterone, 17α-hydroxyprogesterone, 
androstenedione and testosterone.233 The role of testosterone (see Chapter 2) and androstenedione 
(section 5.1.3.2) have been discussed. Progesterone is an essential steroid in the female reproductive 
 
Figure 5.4: The catalytic reactions of CYP17. There is an initial hydroxylation at C17 followed by a second 
oxidation step to cleave formaldehyde and form a keto group at C17  
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cycle whereby it ensures the development of fertile gametes before ovulation. Both progesterone and 






5.1.3.4 CYP21 and CYP11 
The multifunctional glucocorticoids are synthesised by the adrenal glands. They are essential in the 
regulation of the immune system, metabolism and maintaining bodily homeostasis.65 They are 
metabolised form two progestogen intermediates; namely progesterone and 17α-hydroxyprogesterone 
into 11-deoxycorticosterone and 11-deoxycortisol respectively (Fig. 5.6).233 The initial reaction is 
catalysed by CYP21. CYP21 hydroxylates the progestogens at C21 utilizing a NADPH and 02 molecule.
233 
The approximately 56 kDa protein is coded by two genes, with only one gene (cyp21a) producing the 
active enzyme.289 CYP21 (like most steroidogenic CYPs) is located in the endoplasmic reticulum. 
Figure 5.5: The oxidation of the C3 alcohol of pregnenolone and androstenedione by 3β-HSD. This reaction 
requires the cofactor NAD
+ 
which is reduced in the reaction. The next step is the isomeration of the alkene 
which migrates from C5 to C4 
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Following catalysis, 11-deoxycorticosterone and 11-deoxycortisol are transported to inside the 




The second step in glucocorticoid synthesis is the β-hydroxylation at C11 by CYP11. The reaction occurs 
in the inner mitochondrial membrane to yield the active hormones aldosterone and cortisol (Fig. 5.6).290 
There are two genes that code for two isoforms of CYP11 with approximately 97% sequence homology; 
namely, cyp11b1 and cyp11b2.291  
5.1.3.5 17β-HSD 
17β-HSD plays a major role in the synthesis of both androgens and estrogens. The functionality of 17β-
HSDs is limited to sex hormone synthesis (it has no role in glucocorticoid synthesis).233 The enzymatic 
reaction occurs via the reduction of the C17 ketone to yield a β-alcohol.292 The steroid dehydrogenase 
utilizes NADH. Perhaps the most important reaction catalysed by 17β-HSD is the conversion of 
androstenedione to testosterone. A reaction essential for the healthy sexual growth and development 
in males (Fig. 5.7).292 
 
Figure 5.6: The metabolism of glucocorticoids. The synthesis of active glucocorticoids has two hydroxylation 







There are multiple tissue specific isoforms of 17β-HSD. Each isoform is synthesized by a specific gene to 
produce a protein of approximately 37 kDa.293 The isoforms are primarily found in the gonads and 
placenta. Each isoform catalysed a specific reaction; e.g. 17β-HSD3, the enzyme responsible for 
testosterone synthesis is found exclusively in the testis.294 The role of testosterone has been highlighted 
extensively in Chapter 2. 
17β-HSD is a highly regulated as over expression of hsd17b3 could yield too much testosterone, 
particularly in prepubescent boys. Therefore, the expression of the genes is directly regulated by LH 
action. However, any changes in the expression of this gene could result in significant reductions in 
testosterone production, with potentially negative effects on male growth and development. 
5.1.3.6 CYP19  
The activity of CYP19 in the ovaries is essential for the healthy sexual development of females. CYP19 
catalyses the aromatization of testosterone (Fig. 5.7).295 The reaction is a multi-step process; firstly, two 
oxidations of the C19 methyl group are followed by loss of the formic acid.295,296 The final step is 
aromatization of the A ring to yield E2. Each step requires a single NADPH and O2 molecule. 
CYP19 is coded by a single gene (cyp19a1) which yields a 58 kDa protein.295,297 The expression of CYP19 
is limited to the ovary, placenta and Leydig cells.298,299 Much like testosterone, the synthesis of E2 is 
tightly regulated by LH (as evidenced by the increased production via stimulation with gonadotropin 
Figure 5.7: The primary synthesis of the sex hormones. The first step involves the reduction of the 
7-keto group to form testosterone. In males, this is typically the end point. In females, testosterone 
is further metabolised by CYP19 to yield E2. 
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analogues). The regulation of cyp19a1 is essential to prevent feminization in men as an increase in 
CYP19 expression would likely result in increased excess aromatization of testosterone. This could 
reduce testosterone levels and disrupt the androgen:estrogen ratio.   
The regulation of steroidogenesis is essential in the healthy growth and sexual development of humans. 
From early gestation until late adulthood, steroidogenesis is regulated by a variety of compounds that 
stimulate the up-regulation of the steroidogenic genes. However, exposure to compounds (e.g. DBP) 
has the potential to disrupt the regulation of these genes. This may disrupt the healthy sexual growth 
and development of humans. 
5.2 Research objectives 
The aim of this described in this chapter is to investigate the effects of DBP on the gene expression and 
metabolism of the steroidogenesis pathway in cultured LC-540 cells. 
This will be achieved through following research objectives: 
1. Analyse and quantify the gene expression changes in key genes of the steroidogenesis pathway 
following exposure to DBP utilizing Nanostring® nCounter technology. 
2. Determine and measure any effects of gene changes on the testosterone production in LC-540 
cells following exposure to DBP utilizing a developed ELISA protocol. 
3. Bring all the data together in the present study to determine the potential mechanisms of 





5.3.1 Preparation of Exposure Standards and Media 
This procedure was carried out as described in section 3.3.1 
5.3.2 Preparation of LC-540 Cells 
LC-540 cells (6 flasks) were removed from incubation and placed in the laminar flow cabinet. The spent 
MEM was aspirated and the cells washed with PBS (5 mL). The PBS was aspirated and 2.5% v/v aq 
Trypsin (4 mL) was added to each flask. The cells were left at 37°C for 10 min until the cells fully 
detached. The trypsin was inactivated with MEM (10 mL) and removed via centrifugation (4000 xg/5 
min) and vacuum aspirated. The cell pellets were suspended in MEM (20 mL) and pipetted into a fresh 
75 cm2 culture flask. The cells were incubated for 24 h.  
5.3.3 Exposure of LC-540 Cells 
This procedure was carried out as described in section 3.3.2. The cells were incubated for 72 h following 
exposure. 
5.3.4 Cell Counting 
The 12 flasks were removed from incubation and placed in the laminar flow cabinet. The spent MEM 
was collected into 50 mL centrifuge tubes and frozen at -20°C for testosterone analysis (see 5.3.7). The 
cells were washed with PBS (5 mL) to inactivate any remaining the MEM. The PBS was aspirated and 
2.5% aq v/v trypsin (4 mL) was added. The cells were left to incubate for 10 min until the cells fully 
detached (as observed via inverted microscope). The trypsin was inactivated with MEM (16 mL) and the 
cell suspension was transferred into a 50 mL centrifuge tube. The suspension was then vortex mixed to 
break up any cell clumps. A 1 mL aliquot was taken. A 10 μL aliquot was mixed 1:1 in trypan blue and 




5.3.5 RNA Extraction 
The RNA extraction procedure was carried out in conjunction with Dr Ellen Podivinsky. This section 
represents joint work.  
Pelleted cells were removed from -80°C and gently thawed on ice. The cells were suspended at 
approximately 15,000 cells/µL in RTL lysis buffer supplemented with 1% v/v 2-mercaptoethanol.  Cells 
were suspended and lysed by gentle vortex mixing followed by aspiration using a 1 mL micropipettor 
tip.  Genomic DNA was removed from the samples by centrifugation through a gDNA removal column at 
8000xg (max) for 30 s.  Aliquots ere added into Eppendorf tubes and stored at -80°C prior to analysis.   
5.3.6 Gene Expression Assay 
The gene expression assay was carried out by NZ Genomics Ltd (Dunedin, NZ). 
5.2.6.1 Code Sets 
A custom nCounter CodeSet of reporter and capture probes for rat genes was obtained from Nanostring 
Technologies. The CodeSet also contained 6 proprietary positive Control probes and their RNA targets, 
plus 8 proprietary negative Control probes; provided by Nanostring Technologies (Seattle, Washington, 
USA).  
5.2.6.2 Gene Expression Assay 
Gene expression was assayed using the NanoStrings Technologies nCounter Gene Expression Assay 
system. Cell lysate from approximately 15,000 cells was processed in a 5 µL total reaction volume using 
the standard nCounter gene expression protocol for this sample type.  Data acquisition was performed 
using a GEN2 Digital Analyzer with the "Max" Field of View setting (555 images per sample; 5 hour scan 
per cartridge). 
5.2.6.3 Data and Statistical Analysis 




A background ‘no-gene expression’ (NE) threshold level was calculated from negative control 
NanoString nCounter® data, with the mean of negative control + 1 standard deviation taken as the 
baseline threshold for gene expression.  Expression levels for target genes were normalized against Actb 
and Hprt1 endogenous control gene expression levels.  Gene expression fold-change was calculated for 
normalized NanoString nCounter® data for exposed cultures compared to control cultures and a 
Student’s t-test was used to determine the probability that differences between control and exposed 
cultures were significant.  The threshold for a fold change was a fold change >1.4 and a P value < 0.075. 
5.3.7 MEM extraction 
The spent MEM was thawed at 4°C overnight. MEM (5 mL) was filtered through a 0.22 μm cellulose 
acetate sterile syringe filter. The media was extracted as described in section 4.3.2.4. The extract was 
dissolved in testosterone buffer (500 μ) and stored at 4°C prior to testosterone analysis. 
5.3.8 Testosterone Analysis 
The testosterone ELISA was performed by Dr John Lewis at the CHL, Christchurch, New Zealand. The 









5.4.1 Changes in Expression of Key Testosterone Genes 
The control exposure group (i.e. 0 µg DBP/mL) was used as the zero point in determining the fold 
changes. Data were normalised against two housekeeping genes; namely Actb and Hprt1. Three major 
changes in gene expression were found (Fig. 5.8). Firstly, hsd17b3 had a 2.7-fold and 3.1-fold decrease 
at 0.1 µg DBP/mL and 1 µg DBP/mL respectively. Secondly, cyp19a1 was found to have a 4.6-fold 
increase at 1 µg DBP/mL exposure level. The final gene expression change was of AR, which had modest 
fold increases of 1.1 and 1.4 at 0.1 µg DBP/mL and 1 µg DBP/mL respectively. The expression of esr1, 
esr2, lhcgr, cyp21a1 and cyp11b2 remained unchanged. 
 
 
   
 
 
Figure 5.8: The gene expression changes of key genes in testosterone biosynthesis. The gene hsd17b3 is 
approximately 3-fold lower in both exposure groups. The genes cyp19a1 and ar were up-regulated by 4.6-fold 
and 1.4-fold respectively in the higher exposure level. Many genes remained unchanged including genes for 
glucocorticoid synthesis, ERs and LHRs. 
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5.4.2 Testosterone production in LC-540 Cells following DBP exposure  
The testosterone production in LC-540 cells was measured via ELISA (Fig. 5.9). The levels of testosterone 
are significantly decreased in both exposure levels following the 72 h incubation with DBP. The 
testosterone levels are normalised against cell count. The control group has an average testosterone 
concentration of 79.9 pg/106 cells. Following DBP exposure the testosterone concentration decreases to 




Figure 5.9: The production of testosterone per million LC-540 cells following exposure to DBP. The testosterone 





5.5.1 Gene Expression Changes 
Nanostring nCounter technology is a relatively new methodology for analyses of gene expression. The 
assay itself bridges the two more conventional gene expression assays; namely microarray and real time 
polymerase chain reaction (RT-PCR). The assay itself has a key advantage; i.e. the sensitivity of RT-PCR 
without the need to convert RNA to cDNA. As such, Nanostring nCounter technology provides an 
excellent opportunity to analyse the effects of DBP on genes in cultured Leydig cells. The present study 
clearly demonstrates the gene expression changes in response to DBP exposure. 
5.5.1.1 Downregulation of hsd17b3 
The gene expression of hsd17b3 was downregulated 2.7 and 3.1 fold following exposure to 0.1 µg 
DBP/mL and 1 µg DBP/mL respectively (Fig. 5.8). The protein coded for by hsd17b3, 17β-HSD, is a critical 
enzyme in testosterone biosynthesis as it converts androstenedione into testosterone in Leydig cells. 
The downregulation of this gene may lead to a reduction in the transcription of 17β-HSD, leading to a 
reduced capacity of the Leydig cell to produce testosterone. 
As discussed in chapter 2, testosterone is critical in the growth, development and maintenance of the 
male phenotype beginning at early gestation and continuing throughout life. During early gestation, 
testosterone and DHT act upon ARs to promote the transcription of growth factors. These growth 
factors ensure the development of the Wolffian ducts to form the testes and external genitalia. This 
process is highly sexually dimorphic as the same tissues become the female genitalia in female embryos 
when under control of E2. The descent of the testes into the scrotum is entirely dependent of the 
paracrine signalling induced regression of ECMs of gubernaculum cells (which prevent the teste form 
entering the scrotum). If there is inadequate testosterone produced by FLCs in the embryo, it is likely 
that the guburnaculum cells will not fully regress. The result of this is likely undescended testis (i.e. 
cryptorchidism). Cryptorchidism has been widely demonstrated to be a result of embryological 
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exposure to DBP. Therefore, the gene expression changes of hsd17b3 could explain the pathogenesis of 
this disease in rats exposed to DBP. 
Testosterone is also essential in the development of the penis, which is dependant of the activation of 
ARs in penile glans and the urethral epithelial cells. Therefore, if testosterone production is decreased, 
there is the possibility that there could be an inadequate development of the urethra. This is known as 
hypospadias and is commonly observed following embryological exposure to DBP. A key observation of 
the present study is that the down-regulation of hsd17b3 occurs at both exposure levels; i.e. at the 
normal population and occupational daily exposure levels. Therefore, the present study demonstrates 
that the exposure to DBP at the TDI can affect Leydig cells via gene regulatory changes. These changes 
are likely to have effects on male embryos. 
Reduced capacity to produce testosterone via the down-regulation of hsd17b3 is a very probable cause 
of the feminizing effects of DBP exposure. However, the gene expression results also give rise to the 
possibility of increased E2 synthesis which could significantly affect male growth and development. 
5.5.1.2 Upregulation of CYP19 
The gene expression results demonstrate that exposure to DBP at the occupational daily exposure level 
(1 µg DBP/mL) upregulates the expression of cyp19a1, the gene that codes for the enzyme CYP19 (also 
known as aromatase). The primary functionality of this enzyme is the conversion of testosterone into 
E2. The production of E2 is directly responsible for feminization of cells and organisms. Therefore, 
upregulation of this gene could have a two-fold role in the disruption of male reproductive health. 
Firstly, along with the reductions in hsd17b3 expression, an increase in the expression of cyp19a1 would 
further decrease the capacity of a Leydig cell to produce adequate testosterone (such effects of this 
highlighted above). Secondly, an subsequent increases in E2 production would have the potential to 
disrupt the androgen:estrogen ratio. This is particularly damaging to the developing embryo. The initial 
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phase of teste descent requires the regression of the CSL (see chapter 2). While testosterone does not 
play a major role in this process (INSL3 is the key androgenic factor), the CSL can be reinforced by the 
activity of E2. In a developing male embryo, this could prevent total regression of the CSL and lead to 
cryptorchidism.   
Overall the dual regulatory changes of hsd17b3 and cyp19a1 demonstrate a mechanism of reduced 
testosterone synthesis and an increased potential of feminization. It is important to note that there 
were no major changes in gene expression of esr1 or esr2 which would be a strong indicator of 
increased E2 synthesis. Both esr1 and esr2 were up-regulated by 1.4 and 1.9 fold respectively. However, 
the respective P values were 0.186 and 0.707 and so fell well below the threshold for a statistically 
significant fold change. Interestingly, the up-regulation of AR expression was statistically significant. 
5.1.1.3 Increased AR Expression 
The expression of AR was increased at the higher exposure level by 1.4 fold with a P value of 0.03. Such 
an increase AR expression seems counterintuitive as any reductions in testosterone biosynthesis would 
presumably reduce the expression of the AR. However, the observed increase in AR expression may in 
fact be an indicator of reduced testosterone synthesis or feminizing pressure. This has been shown in 
other studies which demonstrate increases in AR in prostate cells following exposure to the 
xenoestrogen, BPA.70 If the production of testosterone reduces, the cell could possibly increase AR 
expression in a potential scavenger mechanism in an attempt to increase the possibility of testosterone 
binding to and activating the AR. 
5.1.1.4 The Unchanged Expression of Several Key Genes 
Several key genes remained unchanged following exposure to DBP including cyp11b1, cyp21a1 and 
lhcgr. These negative results provide insight allow for the potential elimination of several mechanisms 
of toxicity. The unchanged expression of cyp11b1 and cyp21a1 despite reductions in hsd17b3 suggest 
that the steroidogenic pathway may not change the direction of flux in response to changes in the genes 
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responsible for testosterone synthesis. This contradicts previous reports of increased cortisol synthesis 
following DBP exposure.67 This may be due to the cell type differences; the present study used LC-540 
cells whereas the other study used R2C cells. 
The unchanged expression of lhcgr also suggests that the reductions in testosterone likely do not occur 
via reductions in the hormonal stimulation via gonadotropins.  
5.5.2 Reduction in Testosterone Production in DBP-exposed LC-540 Cells 
Many hundreds of genes can change following exposure to potentially toxic compounds. However, such 
changes in gene expression do not always carry through to the translational level. Indeed, the 
proteomics and metabolomics can be considered stronger indicators of the effects of exposure to such 
compounds. The proteomics are perhaps more difficult to measure, especially in LC-540 cells as the 
enzymes are almost certainly at very low concentrations. This can prevent the analysis via Western 
Blotting. Therefore, it is essential to determine metabolism of testosterone in the culture medium 
following exposure to DBP. If there are changes in metabolism combined with changes in gene 
expression strongly implies that protein synthesis is also affected. 
The ELISA analysis of used culture medium found that there was a significant drop in the production in 
testosterone when compared to the no exposure group (Fig. 5.9). The base level of testosterone 
production was found to be approximately 80 pg/106 cells. The cells exposed to DBP had approximately 
half the capacity to produce testosterone at 42 pg/106 cells and 38 pg/106 cells at 0.1 µg DBP/mL and 1 
µg DBP/mL exposure levels respectively. The slight variability in testosterone production between the 
two exposure levels matches the gene expression results which had a mere 0.4 fold difference in 
hsd17b3 expression. 
The levels of E2 were not analysed during this thesis. As the levels of testosterone are much lower in LC-
540 cells than primary cells, if the gene changes of cyp19a1 translated into increased aromatase activity 
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there is the possibility of changes in the levels of E2. However, as the levels would be extremely low, 
ELISA or radioimmunoassay would not be sensitive enough. A potential method could be isotope 
dilution mass spectrometry. More work needs to be to develop this method for the detection of E2. 
There are several limitations in the research described in this chapter. Firstly, the gene expression assay 
only focused on two exposure levels. This prevents any identification of a dose-response relationship. 
Further work needs to be done to analyse the gene expression changes following DBP exposure at a 
range of concentrations. The gene expression assay only analyses a few genes in steroidogenesis. This 
limited scope does not allow for the full elucidation of the gene expression changes following DBP 
exposure. More work needs to be done to evaluate the effects of DBP on StAR, 3β-HSD and other 
steroidogenic CYPs. The lack of proteomics prevents the absolute conclusion that the gene changes to 
hsd17b3 or cyp19a1 carry through to the protein level. The ELIZA data suggest the genes are likely 
changed but a reduction in testosterone could be due to number of effects on steroidogenesis. Western 







The LC-540 cells are a robust model system. The present study used them to significant success as a 
model system for the toxicity of DBP in vivo. The biochemistry of LC-540 coupled with their ease in 
culture provided an excellent basis for the other experiments in the present; i.e. the ability to produce 
adequate testosterone and maintain their biochemistry in long term cultures. 
DBP metabolism in LC-540 cells is in contrast to other metabolism studies in rats. This is due to the 
excess glucuronidation of MBP. The presence of estrogenic molecule, M4B-4HP was not detected. 
However, more work is needed to determine it is produced. The presence of M4B-4HP (or another 
estrogenic metabolite) was implied by the estrogenic activity in MCF-7 cells following exposure to DBP. 
The present study presents a wide range of data that demonstrates the dual mechanism of toxicity of 
DBP in cultured cells. Firstly, DBP alters the expression of key genes in testosterone biosynthesis. The 
expression of hsd17b3 is significantly reduced. ELIZA analysis suggests that this down-regulation 
diminishes the capacity of LC-540 cells to produce testosterone. The expression of cyp19a1 is 
simultaneously up-regulated. This could metabolise the already reduced testosterone levels into E2. 
This could have two roles, further reduction of the testosterone levels with the concomitant feminizing 
pressure via increases in E2 levels. The second mechanism of toxicity is via the minor conversion of DBP 
into M4B-4HP. This likely acts as a xenoestrogen, feminizing tissues and cells.  
It is therefore possible that exposure to DBP at normal population exposure levels results in male genital 
developmental changes consistent with the increased rates of hypospadias and cryptorchidism 
previously reported.179 Prolonged indirect exposure from the ingestion, inhalation and dermal 
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